# Clinical and Preclinical Systematic Review of Astragalus Membranaceus for Viral Myocarditis

Authors: Qun Zheng; Zhuang Zhuang; Zi-Hao Wang; Li-Hui Deng; Wang-Jun Jin; Zi-Jun Huang; Guo-Qing Zheng; Yan Wang
Journal: Oxidative Medicine and Cellular Longevity
 (2020)

---

## Abstract

Astragalus membranaceus (AM) is a traditional Chinese medicine, which possesses a variety of biological activities in the cardiovascular systems. We conducted a clinical and preclinical systematic review of 28 randomized clinical control studies with 2522 participants and 16 animal studies with 634 animals to evaluate the efficacy, safety, and possible mechanisms of AM for viral myocarditis (VM). The search strategies were performed in 7 databases from inception to January 2020. Application of the Cochrane Collaboration’s tool 7-item checklist, SYRCLE’s tool 10-item checklist, and Rev-Man 5.3 software to analyze the risk of bias of studies and data. The results show the score of clinical study quality ranged from 3 to 7 points with an average of 3.32, and the score of animal study quality ranged from 2 to 5 points with an average of 3. In clinical study, AM significantly reduced serum myocardial enzymes and cardiac troponin I levels and improved the clinical treatment efficiency in VM patients compared with the control group (P<0.05). There was no significant difference in the incidence of adverse reactions (P>0.05). Significant increase of the survival rate and decrease of the cardiac cardiology score, cardiac enzymes, and cardiac troponin I were compared with the placebo group in animal studies (P<0.05). The possible mechanisms of AM are largely through antivirus and antivirus receptors, anti-inflammatory, antioxidation, antiapoptotic, antifibrosis, and reducing cardiac calcium load. In conclusion, the findings suggested that AM is a cardioprotection candidate drug for VM.


---

## Body

## 1. Introduction

Viral myocarditis (VM) is defined as the inflammatory disease that injured the muscular tissues of the heart, which refers to the pathological lesion including focal or diffuse myocardial cell degeneration and necrosis, interstitial inflammatory cell infiltration, and fibrous exudation caused by viruses [1]. The acute inflammation may develop into subacute and chronic gradually to tissue remodeling, fibrosis, and loss of myocardium architecture and contractile function finally leading the myocarditis of dilated cardiomyopathy (DCM) [2]. It may cause acute heart failure (AHF) and sudden death which is counted at 10% of total sudden death [3]. In addition, the global incidence of myocarditis estimates about 10 to 20 cases per 100 000 of the population, and with the improvement of diagnosis, the prevalence and incidence expected 46% increases in 2030 [4]. According to the causal pathophysiology and clinical symptom of VM, three main treatments including conventional medical treatment, immunomodulatory therapy, and immunosuppressive therapy are used [5]. However, establishing the potential benefits of immunomodulators and antiviral therapy is currently at the preliminary research stage [6]. Although great progress such as intra-aortic balloon pump, ventricular assist device, or extracorporeal membrane oxygenation has been reached in the treatment of cardiac end-point events, the more important goal is to prevent or delay their progress and prevent complications in VM patients [7]. Thus, how to effectively treat VM and prevent AHF has attracted more and more attention to the world.Astragalus membranaceus (AM) is a famous Qi-tonifying and immunomodulating herb in traditional Chinese medicine [8]. The main components of AM include flavonoids, saponins, polysaccharides, amino acids, and trace elements [9]. It has been widely used as a natural immunomodulator in the treatment of many immune diseases including nephritis [10], immune reaction of cancer [11], and systemic lupus erythematosus [12], and it also showed efficacy in protecting the myocardium in cardiovascular diseases [13]. In recent years, clinical and basic studies have reported the positive therapeutic effect of AM for VM. However, the scattered clinical evidence and uncertain mechanisms limited the application of AM in the clinic. Therefore, in the present study, we are aimed at comprehensively and systematically evaluating the efficacy, safety, and possible mechanisms of AM for VM from clinical and preclinical aspects.


## 2. Methods

### 2.1. Data Sources and Search Strategies

A systematic literature search for the true randomized and controlled studies (RCTs) [14] and animal experimental studies of AM for VM was carried out using PUBMED, EMBASE, Web of Science, Cochrane library, China National Knowledge Infrastructure, Wanfang, and VIP database. All search strategies were performed from inception to January 2020 with the search keyword: “Astragalus” AND “Viral myocardial”. Besides, reference lists from the resulting publications and reviews were searched carefully for the potential eligible studies.


### 2.2. Eligibility Criteria

Two authors selected the studies independently by screening the abstracts and full texts according to the eligibility criteria. Clinical research was included if it met the following criteria: (1) true RCTs of AM for VM with the accepted methodology for randomization: the study which randomized sequence was generated by randomized sequence, calculator, or computer random number generator was included preferentially; coin-tossing or drawing straws in the absence of the participant to decide which group the next participant would be assigned to were also considered eligible randomization techniques [14]; (2) the selected participant should match VM diagnose [2, 15, 16]; (3) the treatment group involved AM as monotherapy or plus basic treatment with unrestricted dosage, formulation, route of administration, and administration time, and the control group received basic treatment, placebo, basic treatment plus placebo, or no treatment as treatment; (4) the primary outcome measures were mortality or survival rate and/or the main cardiovascular events and/or myocardial enzyme and/or cardiac troponin level and/or the heart function index of ultrasonic cardiogram. We adopted the efficiency of clinical therapy and adverse reaction as the second outcome measures. Animal research was included if it met the following criteria: (1) controlled studies assessing the in vivo administration of AM for VM established by various ways were included; (2) the treatment group involved AM as monotherapy with unrestricted dosage, formulation, route of administration, and administration time, and the control group received placebo or no treatment as treatment; (3) the primary outcome measures were mortality and/or survival rate and/or cardiac pathology and/or myocardial enzyme and cardiac troponin level and/or the heart function index of ultrasonic cardiogram, while the second outcome measures were cardioprotective mechanisms of AM. Exclusion criteria of the clinical and animal researches were as follows: (1) not true RCT study or animal study (in vitro studies, case reports, clinical trials with unaccepted methodology for randomization, reviews, abstracts, comments, and editorials); (2) compare with other Chinese herbals; (3) treatment with AM conjunction with other compounds in animal study; (4) duplicate publications; (5) no any primary outcome indicator were involved or incomplete date; (6) no control group; (7) not VM model.


### 2.3. Data Extraction

The information were extracted from included studies by two independent authors using a predefined form. Clinical study extracted author, year, the number of participants, ratio of male and female, the therapeutic regimen for treatment and control groups, adverse reaction, and outcome index from each study. Animal study extracted author, years, detail of animals participating in the experiment, the method to induce the model, the therapeutic regimen for treatment and control groups, and outcome index. Only the outcome data of the highest dose group and peak time point group were included. The graph data were measured by Photoshop when the results were only rendered by graphics, and the response was not received from the corresponding authors.


### 2.4. Quality Estimation of Included Studies

The risk of bias tool recommended by Cochrane Collaboration [17] (The Cochrane Collaboration.http://www.cochrane-handbook.org. (Accessed December 25, 2014)) and SYRCLE’s risk of bias tool [18] was adopted separately to estimate the quality of included clinical and animal studies. Disagreements in the process of selecting studies, extracting data, and assessing the quality of studies were resolved by consensus or arbitration by the correspondence authors.


### 2.5. Statistical Analysis

The RevMan 5.3 was used to dispose the data of detailed outcome where possible; otherwise, the system assessment was adopted. Random (I2>50%) or fixed-effects model (I2<50%) was selected according to the results of heterogeneity estimated by using the Cochrane Q-statistic test and the I2-statistic test. The effect sizes of continuous variable were estimated by utilizing standard mean difference (SMD) with 95% confidence interval (CI), and the effect sizes of bivariate were estimated by utilizing odds ratio (OR) with 95% CI. The Forest plot was used to present meta-analysis results, and the funnel plot was used to assess reported bias when a single index included more than 12 studies. The difference between treatment and control groups was considered statistically significant when P<0.05.


## 2.1. Data Sources and Search Strategies

A systematic literature search for the true randomized and controlled studies (RCTs) [14] and animal experimental studies of AM for VM was carried out using PUBMED, EMBASE, Web of Science, Cochrane library, China National Knowledge Infrastructure, Wanfang, and VIP database. All search strategies were performed from inception to January 2020 with the search keyword: “Astragalus” AND “Viral myocardial”. Besides, reference lists from the resulting publications and reviews were searched carefully for the potential eligible studies.


## 2.2. Eligibility Criteria

Two authors selected the studies independently by screening the abstracts and full texts according to the eligibility criteria. Clinical research was included if it met the following criteria: (1) true RCTs of AM for VM with the accepted methodology for randomization: the study which randomized sequence was generated by randomized sequence, calculator, or computer random number generator was included preferentially; coin-tossing or drawing straws in the absence of the participant to decide which group the next participant would be assigned to were also considered eligible randomization techniques [14]; (2) the selected participant should match VM diagnose [2, 15, 16]; (3) the treatment group involved AM as monotherapy or plus basic treatment with unrestricted dosage, formulation, route of administration, and administration time, and the control group received basic treatment, placebo, basic treatment plus placebo, or no treatment as treatment; (4) the primary outcome measures were mortality or survival rate and/or the main cardiovascular events and/or myocardial enzyme and/or cardiac troponin level and/or the heart function index of ultrasonic cardiogram. We adopted the efficiency of clinical therapy and adverse reaction as the second outcome measures. Animal research was included if it met the following criteria: (1) controlled studies assessing the in vivo administration of AM for VM established by various ways were included; (2) the treatment group involved AM as monotherapy with unrestricted dosage, formulation, route of administration, and administration time, and the control group received placebo or no treatment as treatment; (3) the primary outcome measures were mortality and/or survival rate and/or cardiac pathology and/or myocardial enzyme and cardiac troponin level and/or the heart function index of ultrasonic cardiogram, while the second outcome measures were cardioprotective mechanisms of AM. Exclusion criteria of the clinical and animal researches were as follows: (1) not true RCT study or animal study (in vitro studies, case reports, clinical trials with unaccepted methodology for randomization, reviews, abstracts, comments, and editorials); (2) compare with other Chinese herbals; (3) treatment with AM conjunction with other compounds in animal study; (4) duplicate publications; (5) no any primary outcome indicator were involved or incomplete date; (6) no control group; (7) not VM model.


## 2.3. Data Extraction

The information were extracted from included studies by two independent authors using a predefined form. Clinical study extracted author, year, the number of participants, ratio of male and female, the therapeutic regimen for treatment and control groups, adverse reaction, and outcome index from each study. Animal study extracted author, years, detail of animals participating in the experiment, the method to induce the model, the therapeutic regimen for treatment and control groups, and outcome index. Only the outcome data of the highest dose group and peak time point group were included. The graph data were measured by Photoshop when the results were only rendered by graphics, and the response was not received from the corresponding authors.


## 2.4. Quality Estimation of Included Studies

The risk of bias tool recommended by Cochrane Collaboration [17] (The Cochrane Collaboration.http://www.cochrane-handbook.org. (Accessed December 25, 2014)) and SYRCLE’s risk of bias tool [18] was adopted separately to estimate the quality of included clinical and animal studies. Disagreements in the process of selecting studies, extracting data, and assessing the quality of studies were resolved by consensus or arbitration by the correspondence authors.


## 2.5. Statistical Analysis

The RevMan 5.3 was used to dispose the data of detailed outcome where possible; otherwise, the system assessment was adopted. Random (I2>50%) or fixed-effects model (I2<50%) was selected according to the results of heterogeneity estimated by using the Cochrane Q-statistic test and the I2-statistic test. The effect sizes of continuous variable were estimated by utilizing standard mean difference (SMD) with 95% confidence interval (CI), and the effect sizes of bivariate were estimated by utilizing odds ratio (OR) with 95% CI. The Forest plot was used to present meta-analysis results, and the funnel plot was used to assess reported bias when a single index included more than 12 studies. The difference between treatment and control groups was considered statistically significant when P<0.05.


## 3. Results

### 3.1. Study Selection

For clinical studies, a total of 173 studies were extracted from initially collected 861 studies after scanning the titles and abstracts. Detailed inspection was performed to remaining full-text studies; 145 studies were excluded according to the inclusion and exclusion criteria. For animal studies, a total of 142 studies were extracted from initially collected 762 studies after scanning the titles and abstracts. Detailed inspection was performed to remaining full-text studies; 126 studies were excluded according to the inclusion and exclusion criteria. Finally, 28 randomized controlled clinical trials and 16 animal studies were included. The detailed search process was shown in Figure1.Figure 1
Summary of the process for identifying candidate studies. (a) Search strategy for clinical studies. (b) Search strategy for animal studies.
(a)(b)


### 3.2. Characteristics of Included Studies

#### 3.2.1. Clinical Studies

The overall characteristics of included clinical studies are generalized in Table1. All included studies were RCTs published in Chinese from 2006 to 2019. Among them, 9 studies [19–27] are involved in adult with VM and 19 studies [28–46] in children with VM. With regard to the information of the participants in the experiment, a total of 1276 subjects were included in the intervention group, while a total of 1246 subjects in the control group. The baseline of the two groups was comparable. Twenty-one studies [19–22, 24, 26, 27, 29, 31, 33–35, 37, 39, 42–46] implemented the dose gradient of AM ranged from 5 ml•d−1 to 200 ml•d−1 by intravenous drip infusion administration. In addition, 0.5 ml•kg−1•d−1 Astragalus membranaceus injection (AI) was administered by intravenous drip infusion in 1 study [30], 1 ml•kg−1•d−1 in 1 study [36], 2 ml•kg−1•d−1 in 1 study [28], 2 g•kg−1•d−1 in 1 study [41], and 20 g•kg−1•d−1 in 1 study [25]; and the oral dosage of AM granule was adjusted according to age (2 g/d (age≤2Y), 3 g/d (2Y<age≤4Y), 4 g/d (4Y<age≤6Y), and 8 g/d (age>6Y)) and was reported in 2 studies [32, 38]. Except 1 study [37] reported that it only contrasted the curative effect of AI and placebo without additional treatment, the remaining 27 studies reported that the intervention group and the control group were given basic treatment (including antivirus, anti-infection, antiarrhythmia, and nourishing myocardium), and AI or granules were added to the intervention group. Detailed information on AM in each clinical study is displayed in Table 2. As for follow-up period, 18 studies [20, 22–25, 27–30, 33–38, 40, 42, 43, 45] lasted 2 weeks, 7 studies [21, 26, 31, 32, 41, 44, 46] lasted 4 weeks, 1 study [19] lasted 6 weeks, and 1 study [39] lasted 46 days. Creatine kinase (CK) was utilized as primary outcome measure in 11 studies [22, 23, 25, 28–31, 35, 37, 41, 45]; creatine kinase isoenzyme (CK-MB) in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41]; lactate dehydrogenase (LDH) in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45]; glutamic pyruvate transaminase (AST) in 7 studies [19, 25, 27, 38, 41, 42, 45]; and cardiac troponin iroponin I (cTnI) in 8 studies [21, 23, 26, 28–30, 35, 37]. Ejection fraction (EF) was utilized as a primary outcome measure in 1 study [20], and none of the included studies were involved in mortality and major cardiovascular events. The clinical efficacy of AM in the treatment of VM was utilized as a secondary outcome measure in 26 studies [19–23, 25–28, 30–46] and the adverse reactions in 10 studies [19, 26–29, 32, 33, 36, 37, 39].Table 1
The characteristic of clinical studies.
Study (years)Number (n = male/female); mean age (years); course of disease (days)TreatmentsDuration of treatmentAdverse reactionsOutcome indexIntergroup differencesExperimental groupControl groupExperimental groupControl groupDu 201948 (25/23)48 (26/22)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + sodium creatine phosphate for injection (1 g, qd)2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.81±2.247.63±2.16NMNMLi et al. 201946 (25/21)46 (26/20)By intravenous drip infusion of AM injection (2 ml/kg, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(5) TNF-α(6) IL-6(7) Effect of arrhythmia(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.055.67±1.825.83±1.72NMNMQi et al. 201960 (NM)60 (NM)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS500ml+basic treatmentAdenosine disodium triphosphate, coenzyme A and insulin for injection20mg,qd+fructose sodium diphosphate injection (5 g, bid)4 weeksN(1) Effective rate(2) hs-CRP(3) CK-MB(4) cTnI(5) TNF-β(6) IL-10(7) IL-17(8) IL-21(9) miR-146b(10) miR-155(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.05(10) P<0.05NMNMNMNMZhang et al. 201946 (22/24)45 (20/25)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS200ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + Inosine injection + fructose 1,6-diphosphate injection2 weeksN(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) CD4+/CD8+(6) EF(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.0536.12±5.8735.52±5.47NMNMZheng 201945 (21/24)44 (23/21)By intravenous drip infusion of AM injection (20 ml, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + trimetazidine6 weeksY(1) Recover time of clinical symptoms(2) Recovery time of arrhythmia(3) CK-MB(4) AST(5) LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0548.47±15.2549.15±16.1815.11±3.2516.01±3.31Liu et al. 201843 (20/23)43 (24/19)By intravenous drip infusion of AM injection (0.5 ml/kg, qd) in 5% GS250ml+basic treatmentAntiviral drugs + vitamin C + fructose + coenzyme Q10 + creatine phosphate injection (1.0 g, qd)2 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.057.36±1.487.74±1.65NMNMGui 201767 (34/33)67 (35/32)By oral administration of AM granule (age≤2 years 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentVitamin C + energy mixture injection + vitamin E + coenzyme Q + coenzyme A4 weeksY(1) Effective rate(1)P<0.055.4±0.55.7±0.3NMNMZhang et al. 2017B36 (20/16)36 (14/22)By intravenous drip infusion of AM injection (10 ml, qd) in 5% GS + basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + coenzyme Q104 weeksN(1).Effective rate(2) CK(3) CK-MB(4) TNF-α(5) IL-10(6) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.055.29±2.915.38±2.86NMNMZhou 201750 (26/24)50 (28/22)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q1015 daysN(1) Effective rate(2) CK(3) CK-MB(4)LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0535.9±2.736.4±3.4NMNMLi et al. 2016A34 (21/13)34 (19/15)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentVitamin C + vitamin E + coenzyme Q10 + energy mixture injection2 weeksN(1) Effective rate(2) INF-γ(3) IL-4(4) INF-γ/IL-4(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.058.54±4.389.14±5.266.21±3.175.26±2.79Xing 201645 (29/16)5.4±1.714.7±3.241 (28/13)5.1±1.615.1±3.4By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q103 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(6) CD3+(7) CD4+(8) CD8+(1)P<0.01(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.05(8) P<0.05Wu 201647 (21/26)47 (24/23)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + energy mixture injection2 weeksN(1) Effective rate(2) LDH(3) cTnI(4) CD3+(5) CD4+(6) CD8+(7) NK(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.0126.7±10.126.4±10.5NMNMWu et al. 201640 (24/16)40 (22/18)By intravenous drip infusion of AM injection (10-20 ml, qd) in NS50ml+basic treatmentAntiviral drugs + fructose2 weeksY(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) NK(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.48±1.406.44±1.432.13±0.682.11±0.66Gao 201560 (27/33)60 (25/35)By intravenous drip infusion of AM injection (20 g, qd) in 5% GS500ml+basic treatmentPolarization liquid + vitamin C + coenzyme Q102 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0538.5±7.237.4±7.031.2±6.932.1±8.0Lou 201548 (34/14)48 (25/23)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS 250 mlPolarization liquid2 weeksY(1) Effective rate(2) TNF-α(3) INF-8(4) INF-6(5) CK(6) CK-MB(7) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.056.01±1.25.8±1.5NMNMTao 201539 (22/17)39 (24/15)By intravenous drip infusion of AM injection (1 ml/kg, qd) in 5% GS100ml+basic treatmentAntiviral drugs (ribavirin) + coenzyme A + ATP + vitamin C15 daysY(1) Effective rate(2) Recover time of clinical symptoms(3) Recover time of clinic syndrome myocardial enzyme(1)P<0.05(2) P<0.05(3) P<0.056.2±2.46.6±2.77.5±7.67.2±7.3Zhao et al. 201589 (51/38)89 (44/45)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q10 + inosine tablets + polarization liquid2 weeksN(1) Effective rate(2) SOD(3) MDA(4) GST(5) NO(6) TNF-α(7) INF-γ(8) IL-8(9) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.0529.4±11.830.1±12.7NMNMBan 201434 (20/14)34 (18/16)By intravenous drip infusion of AM injection (2 g/kg, qd) in 5% GS250ml+basic treatmentCoenzyme Q10 + ATP + vitamin C4 weeksN(1) CK(2) CK-MB(3) LDH(4) AST(5) α-HBDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.058±2.019±1.28NMNMWang et al. 201430 (16/14)30 (18/12)By intravenous drip infusion of AM injection (20 ml, qd) in 10% GS250ml+basic treatmentAntiviral drugs (acyclovir) + vitamin C + coenzyme A46 daysY(1) Effective rate(1)P<0.059.3±2.812.1±2.2NMNMLiang 201425 (14/11)25 (13/12)By intravenous drip infusion of AM injection (10-20 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q104 weeksN(1) Effective rate(2) SOD(3) MDA(4) NO(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.9±3.68.1±3.216.2±2.514.1±2.3Kang 201443 (22/21)43 (21/22)By intravenous drip infusion of AM injection (30 ml, qd) in 10% GS 250 mlNM15 daysN(1) Effective rate(2) Effect of arrhythmia(1)P<0.05(2) P<0.05NMNMNMNMZhang 201457 (32/25)56 (32/24)By oral administration of AM granule (age≤2 years, 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentAntiviral drugs (ribavirin) + fructose + coenzyme Q10 + vitamin C + gamma globulin2 weeksN(1) Effective rate(2) CK-MB(3) LDH(4) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.053.7±1.53.8±1.57.4±0.87.3±0.8Liu et al. 201332 (18/14)32 (20/12)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentNM2 weeksN(1) Effective rate(2) IL-23(3) IL-17(4) Th17 cell(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.059.1±5.18.7±4.56.2±3.15.2±2.8Zhang et al. 201334 (17/17)34 (17/17)By intravenous drip infusion of AM injection (50 ml, qd) in 5% GS250ml+basic treatmentEnergy mixture injection + vitamin C + coenzyme Q10 + polarization liquid2 weeksN(1) Effective rate(2) CK-MB(3) ESR(4) AST(5) ALT(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05NMNMNMNMWang 201235 (18/17)35 (20/15)By intravenous drip infusion of AM injection (50 ml, qd) + basic treatmentAntiviral drugs + vitamin C + coenzyme Q10 + polarization liquid + Trimetazidine4 weeksY(1) Effective rate(2) Arrhythmia(3) cTnI(4) Cardiac function(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0555±1160±953±1755±16Dong 201160 (34/26)50 (28/22)By intravenous drip infusion of AM injection (5-20 ml, qd) + basic treatmentAntiviral drugs (ribavirin) + vitamin C + fructose + energy mixture injection30 daysN(1) Effective rate(2) Recovery rate of CK-MB(3) Recovery rate of CK(4) Recovery rate of LDH(5) Recovery rate of AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.56.9NMNMHu 200950 (26/24)50 (27/23)By intravenous drip infusion of AM injection (60 ml, bid) in 5% GS250ml+basic treatmentCoenzyme Q10 + polarization liquid2 weeksY(1) Effective rate(2) Effect of arrhythmia(3) AST(4) CK-MB(5) LDH(6) cTnI(7) NK(8) TNF-α(9) IL-1(10) IL-6(1)P<0.05(2) P<0.05(3) P>0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P>0.05(9) P<0.05(10) P>0.0538±10.135±9.84±0.7 months5±0.6 monthsZhang et al. 2006B33 (20/13)20 (14/6)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + vitamin E + energy mixture injection2 weeksN(1) Effective rate(2) CK(3) AST(4) LDH(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.052±112±11NMNMNote:α-HBDH: α-hydroxybutyric dehydrogenase; hs-CRP: hypersensitive C-reactive protein; miR: microRNA; ALT: alanine aminotransferase; AM: Astragalus membranaceus; AST: aspartate aminotransferase; ATP: adenosine triphosphate; Bid: bis in die; cTnI: cardiac troponin I; CD: cluster of differentiation; CK: creatine kinase; CK-MB: creatine kinase isoenzyme; EF: ejection fraction; ESR: erythrocyte sedimentation rate; GS: glucose injection; GST: glutathione transferase; IL: interleukin; INF-γ: interferon-γ; LDH: lactic dehydrogenase; MDA: malondialdehyde; N: no; NK: natural killer cell; NM: not mentioned; NO: nitric oxide; NS: normal saline; Qd: quaque die; SOD: superoxide dismutase; Th: T helper cell; TNF: tumor necrosis factor; Y: yes.Table 2
Information of AM of clinical study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedDu 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Li et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z19993151Qi et al. 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Zhang et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z20003189Zheng 2019InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Liu et al. 2018InjectionUnknownUnknownUnknownGui 2017GranuleUnknownUnknownUnknownZhang et al. 2017BInjectionUnknownUnknownUnknownZhou 2017InjectionUnknownUnknownUnknownLi et al. 2016AInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094Xing 2016InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLBatch number: 20120829Wu 2016InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Wu et al. 2016InjectionUnknownUnknownUnknownGao 2015InjectionUnknownUnknownUnknownLou 2015InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z33020178Tao 2015InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Zhao et al. 2015InjectionHarbin Shengtai Biopharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020820Ban 2014InjectionUnknownUnknownUnknownWang et al. 2014InjectionDali Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z53021585Liang 2014InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLBatch number: 100226Kang 2014InjectionUnknownUnknownUnknownZhang 2014GranuleUnknownUnknownUnknownLiu et al. 2013InjectionChengdu Di’ao Jiuhong pharmaceutical factory2 g/mLBatch number: 0210094Zhang et al. 2013InjectionUnknownUnknownUnknownWang 2012InjectionUnknownUnknownUnknownDong 2011InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLBatch number: 020213210901082, 0506013Hu 2009InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13021000Zhang et al. 2006BInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094


#### 3.2.2. Animal Studies

The overall characteristics of the included animal study are generalized in Table3. A total of 15 Chinese studies [47–61] and 1 English study [13] on AM for VM published between 2002 and 2017 were included. All studies are involved in 634 experimental animals. Among them, male Balb/c mice were used in 13 studies [13, 47, 49–51, 53, 54, 56–61], female Balb/c mice in 1 study [52], Balb/c mice without mentioning gender in 1 study [55], and male/female SD rats in 1 study [48]. All models of acute VM were established by intraperitoneal injection of a solution containing coxsackievirus B3 (CVB3) virus. Twelve studies [13, 48–51, 53, 56–61] implemented the dose gradient of AM ranged from 2.2 mg•kg−1•d−1 to 90 g•kg−1•d−1. In addition, 1 study [54] used the dosage of AM with 0.4 mg•d−1, 2 studies [52, 55] used 0.4 g•d−1, and 1 study [47] used 0.4 ml•g−1•d−1. Intragastric administration was adopted in 7 studies [13, 53–56, 59, 61] and intraperitoneal injection in 9 studies [47–52, 57, 58, 60]. All included studies reported that the intervention group received AM as monotherapy, while the control group was treated with the same volume of normal saline or nonfunctional liquid therapy or placebo. Detailed information of AM in each animal study is displayed in Table 4. The survival rate of animals was utilized as the primary outcome measure in 4 studies [13, 54, 57, 58], the changes of cardiac pathology or cardiac pathological score in 15 studies [13, 47–55, 57–61], cTnI in 3 studies [13, 47, 50], CK-MB in 3 studies [47, 49, 61], LDH in 2 studies [57, 61], AST in 1 study [57], and none of the included studies involved in the indexes of cardiac function under B-ultrasound. Among secondary outcome indicators for the study of mechanism, tumor necrosis factor (TNF-α) was reported in 4 studies [49, 53, 54, 56]; interleukin-2 (IL-2), interleukin-8 (IL-8), and interleukin-18 (IL-18) in 1 study [52]; nuclear chemokine-1 (MCP-1) in 1 study [51]; macrophage inflammatory protein-2 (MIP-2) in 1 study [50]; superoxide dismutase (SOD) and malondialdehyde (MDA) in 1 study [57]; Caveolin-3 (Cav-3) and Smad family member 3 (Smad3) in 1 study [48]; coxsackievirus and adenoviral receptor (CAR) in surface myocardium in 1 study [55]; sarco endoplasmic reticulum calcium adenosine triphosphatase (SERCA), endothelin-1 (ET-1) and the maximum binding capacity of endothelin receptor maximum binding capacity (ETR Bmax) in 1 study [13]; the replication level of CVB3 in 1 study [59]; the changes of Fas/FasL gene expression in cardiomyocytes in 1 study [60]; and the atrial natriuretic peptide (ANP) in 1 study [13].Table 3
The characteristic of animal studies.
Study (years)Species (age; sex; number = experimental/control)WeightModel (method)Experimental groupControl groupOutcome indexIntergroup differencesZhang et al. 2017ABalb/c mice (4-6 weeks; male; 12/12)16-18 gBy intraperitoneal injection of culture medium containing 1000 PFU/ml CVB3 virus (0.4 ml)By intraperitoneal injection of AM injection (0.4 ml/g, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml/g, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) CK-MB(1)P<0.05(2) P<0.01(3) P<0.01Li et al. 2016BSD rats (7-9 weeks; male/female; 15/15)182±36gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (1.68 g/kg, qd) for 15 d after establishing modelBy intraperitoneal injection of normal saline (20 ml/kg, qd) for 15 d after establishing model(1) Changes of cardiac pathology(2) Caveolin-3(3) Smad-3(1)P<0.05(2) P<0.01(3) P<0.05Jiang 2013Balb/c mice (4-6 weeks; NM; 12/12)NMBy intraperitoneal injection of culture medium containing 2000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 7 d after establishing model(1) Changes of cardiac pathology(2) CK-MB(3) TNF-α(1)P<0.01(2) P<0.01(3) P<0.01Wang et al. 2011Balb/c mice (4 weeks; male; 15/15)12-16 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) MIP-2 mRNA(4) MIP-2(1)P<0.01(2) P<0.05(3) P<0.01(4) P<0.01Cai et al. 2009Balb/c mice (6-8 weeks; male; 20/20)18-22 gBy intraperitoneal injection of culture medium containing 1000 TCID50 CVB3 virus (0.15 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) MCP-1 mRNA(3) MCP-1(1)P<0.05(2) P<0.01(3) P<0.05Zhang et al. 2009Balb/c mice (6-8 weeks; female; 20/20)NMBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (0.4 g, qd) for 21 d after establishing modelBy intraperitoneal injection of normal saline (0.2 ml, qd) for 21 d after establishing model(1) Changes of cardiac pathology(2) IL-2(3) IL-8(4) IL-18(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2007Balb/c mice (5 weeks; NM; 40/40)15-16 gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.4 g, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.3 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Coxsackievirus and adenovirus receptor mRNA(1)P<0.01(2) P<0.01Wu et al. 2007Balb/c mice (4 weeks; male; 20/20)14±2gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.2 ml)By oral gavage of AM oral liquid (0.2 mg, bid) for 10 d after establishing modelBy oral gavage of normal saline (0.2 ml, bid) for 10 d after establishing model(1) Changes of cardiac pathology(2) TNF-α mRNA(3) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05Yao et al. 2007Balb/c mice (5 weeks; male; 20/20)16-20 gBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (30 g/kg, qd) for 5 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml, qd) for 5 d after establishing model(1) Changes of cardiac pathology(2) TNF-α(1)P<0.05(2) P<0.05Chen et al. 2006Balb/c mice (3 weeks; male; 36/31)12-15 gBy intraperitoneal injection of culture medium containing 20000 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (2.2 mg/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) SERCA activity(4) ETR maximum binding capacity(5) ETR equilibrium dissociation constant(6) ET-1(7) ANP(8) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05Zhang et al. 2006ABalb/c mice (4 weeks; male; 30/30)NMBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM granule (30 g/kg, qd) for 5 d after establishing modelBy oral gavage of normal saline for 5 d after establishing model(1) Cardiomyocyte apoptosis rate(2) TNF-α(1)P<0.05(2) P<0.05Guan et al. 2005Balb/c mice (NM; male; 8/6)17.5±1.2gBy intraperitoneal injection of culture medium containing 400 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (90 g/kg, qd) for 9 d after establishing modelBy intraperitoneal injection of normal saline for 9 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(3) AST(4) LDH(5) MDA(6) SOD(7) Affect of electrocardiogram(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05Liu et al. 2004Balb/c mice (45 weeks; male; 50/50)14-16 gBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of phosphate buffered solutions (0.2 ml, qd) for 7 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(1)P<0.05(2) P<0.05Liu et al. 2003Balb/c mice (4-6 weeks; male; 12/12)NMBy intraperitoneal injection of culture medium containing1×109 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline for 7 d after establishing model(1) Changes of cardiac pathology(2) Apoptotic index(3) Fas(4) FasL(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2003Balb/c mice (6-8 weeks; male; 20/20)16-18 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.78 g/kg, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.5 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Virus isolation positive rate(1)P<0.01(2) P>0.05Liu et al. 2002Balb/c mice (NM; male; 10/11)12.8±1.0gBy intraperitoneal injection of culture medium containing9×109 PFU/ml CVB3 virus (0.4 ml)By oral gavage of AM oral liquid (10 g/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) HW/BW ratios(2) Changes of cardiac pathology(3) LDH(4) CK-MB(1)P<0.05(2) P<0.05(3) P<0.01(4) P<0.05Note: d: day; AM: Astragalus membranaceus; ANP: atrial natriuretic peptide; AST: aspartate aminotransferase; Bid: bis in die; cTnI: cardiac troponin I; CK-MB: creatine kinase isoenzyme; CVB3: coxsackievirus B3; ET: endothelin; ETR: endothelin receptor; HW/BW: heart weight/body weight; IL: interleukin; LDH: lactic dehydrogenase; MCP: monocyte chemoattractant protein; MDA: malondialdehyde; MIP: macrophage inflammatory protein; NM: not mentioned; PFU: plaque-forming unit; Qd: quaque die; SERCA: sarco endoplasmic reticulum calcium adenosine triphosphatase; Smad: small mothers against decapentaplegic; SOD: superoxide dismutase; TCID50: median tissue culture infective dose; TNF-α: tumor necrosis factor-α.Table 4
Information of AM of animal study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedZhang et al. 2017AInjectionUnknownUnknownUnknownLi et al. 2016BGranuleNanjing Tongrentang Pharmaceutical Co., Ltd.UnknownBatch number: 140604Jiang 2013InjectionFuda Pharmaceutical Co., Ltd.2 g/mLBatch number: 000617Wang et al. 2011InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Cai et al. 2009InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Zhang et al. 2009InjectionHugang Xinya Pharmaceutical Industry (Yangzhou) Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z32021256Li et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownTraditional Chinese patented medicine WY: Z20003380Wu et al. 2007Oral liquidUnion Hospital affiliated Huazhong University of Science and Technology1 g/LBatch number: 020926Yao et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Chen et al. 2006InjectionFuda Pharmaceutical Co., Ltd.2 g/mLUnknownZhang et al. 2006AGranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Guan et al. 2005InjectionShanghai Tiansheng Pharmaceutical Chemical Industry Research Institute12 g/mLBatch number: 20020108Liu et al. 2004InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLUnknownLiu et al. 2003InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLUnknownLi et al. 2003Oral liquidUnknown2 g/mLUnknownLiu et al. 2002Oral liquidUnknown1 g/mLUnknown


### 3.3. Study Quality

The number of criteria met in clinical studies varied from 3/7 to 7/7 with the average of 3.32 according to the risk of bias tool recommended by Cochrane Collaboration [17] (The Cochrane Collaboration.http://www.cochrane-handbook.org. (Accessed December 25, 2014)), while the number of criteria met in animal studies varied from 2/10 to 5/10 with an average of 3 according to SYRCLE’s risk of bias tool [18]. Detailed results of methodological quality of clinical and animal studies are presented, respectively, in Tables 5 and 6.Table 5
Risk of bias of clinical studies.
StudyABCDEFGTotalDu 2019+———+—+3Li et al. 2019+———+—+3Qi et al. 2019+———+++4Zhang et al. 2019+———+—+3Zheng 2019+———+—+3Liu et al. 2018+———+++4Gui 2017+———+—+3Zhang et al. 2017B+———+++4Zhou 2017+———+—+3Li et al. 2016A+———+—+3Xing 2016+———+—+3Wu 2016+———+—+3Wu et al. 2016+———+—+3Gao 2015+———+—+3Lou 2015+———+—+3Tao 2015+———+—+3Zhao et al. 2015+———+—+3Ban 2014+———+—+3Wang et al. 2014+———+—+3Liang 2014+———+—+3Kang 2014+———+—+3Zhang 2014+———+—+3Liu et al. 2013+———+++4Zhang et al. 2013+++++++7Wang 2012+———+—+3Dong 2011+———+—+3Hu 2009+———+—+3Zhang et al. 2006B++——+—+4Note: A: random sequence generation; B: concealment of allocation; C: blinding of participants and personnel; D: blinding of outcome assessment; E: incomplete outcome data; F: selective reporting; G: other bias; “+” indicates low risk of bias; “-” indicates high risk of bias; and “?” indicates an unclear risk of bias.Table 6
Risk of bias of animal studies.
StudyABCDEFGHIJTotalZhang et al. 2017A+————+—+++5Li et al. 2016B?——+—+—+?+4Jiang 2013———————+?+2Wang et al. 2011?——+———+?+3Cai et al. 2009?——+———+++4Zhang et al. 2009?——————+?+2Li et al. 2007?——————+++3Wu et al. 2007?————+—+?+3Yao et al. 2007?——————+?+2Chen et al. 2006———————+?+2Zhang et al. 2006A?——————+?+2Guan et al. 2005?——————+?+2Liu et al. 2004+——+———+?+4Liu et al. 2003?+—————+++4Li et al. 2003?+———+—+?+4Liu et al. 2002?——————+?+2Note: A: sequence generation; B: baseline characteristics; C: allocation concealment; D: random housing and animal welfare; E: blinding of caregivers and/or investigators; F: random outcome assessment; G: blinding of outcome assessor; H: complete outcome data; I: selective outcome reporting; J: other sources of bias. “+” indicates low risk of bias; “-” indicates high risk of bias; and “?” indicates an unclear risk of bias.


### 3.4. Effectiveness

#### 3.4.1. Outcomes of Clinical Studies

(1) Cardiac Enzymes and Cardiac Troponin. CK-MB was reported in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41], LDH in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45], AST in 7 studies [19, 25, 27, 38, 41, 42, 45], and cTnI in 8 studies [21, 23, 26, 28–30, 35, 37] as primary outcome measures. Among the studies involve in CK-MB, 1 study [37] was designed to contrast the efficacy of AI and placebo for VM; 13 studies [19, 21, 22, 25–31, 35, 38, 41] were designed to contrast the efficacy of AI plus basic treatment and basic treatment. Meta-analysis of the 13 studies revealed significant effects of AI plus basic treatment on decreasing CK-MB in patients with VM (n=1266, SMD −1.58, 95% CI [−1.72 to −1.45], P<0.00001; heterogeneity: χ2=221.59, df=12 (P<0.00001); I2=95%, Figure 2). The remaining one study [37] showed that CK-MB was decreased evidently by AI contrast with the placebo group. Meta-analysis of 10 studies and 7 studies showed separately that AI plus basic treatment could decrease LDH (n=913, SMD −0.89, 95% CI [−1.03 to −0.76], P<0.00001; heterogeneity: χ2=19.43, df=9 (P=0.02); I2=54%, Figure 3) and AST (n=611, SMD −0.82, 95% CI [−0.99 to −0.65], P<0.00001; heterogeneity: χ2=53.14, df=6 (P<0.00001); I2=89%, Figure 4) significantly in patients with VM. As for cTnI, meta-analysis of 8 studies showed significant effects of AI plus basic treatment on reducing cTnI in patients with VM (n=770, SMD −1.71, 95% CI [−1.88 to −1.53], P<0.00001; heterogeneity: χ2=121.49, df=7 (P<0.00001); I2=94%, Figure 5). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in CK-MB, AST, or cTnI.Figure 2
The forest plot: effects of AM for decreasing CK-MB compared with the control group (clinical studies).Figure 3
The forest plot: effects of AM for decreasing LDH compared with the control group (clinical studies).Figure 4
The forest plot: effects of AM for decreasing AST compared with the control group (clinical studies).Figure 5
The forest plot: effects of AM for decreasing cTnI compared with the control group (clinical studies).(2) Effective Rate of Clinical Treatment. The effective rate of clinical treatment was reported in 25 studies [19–23, 25–28, 30–36, 38–46] to contrast the efficacy of AI or AM granule plus basic treatment and basic treatment, except 1 comparative study [37] of AI and placebo. Meta-analysis of the 25 studies showed significant effects of AI plus basic treatment on increasing the effective rate of clinical treatment compared with basic treatment (n=2245, RR 1.24, 95% CI [1.19 to 1.28], P<0.00001; heterogeneity: χ2=16.71, df=24 (P=0.86); I2=0%, Figure 6). The symmetrical publication bias funnel indicated that there is no obvious publication bias in this study (Figure 7). The remaining 1 study also showed that the efficacy of AI in the treatment of VM was significantly better than that in the placebo group (P<0.05).Figure 6
The forest plot: effects of AM for increasing the effective rate of clinical treatment compared with the control group.Figure 7
The funnel plot: effects of AM on an effective rate of clinical treatment.(3) Adverse Reactions. Adverse reactions were reported in 10 studies [19, 26–29, 32, 33, 36, 37, 39]. Serious adverse reactions such as liver and kidney function injury, anaphylactic shock, carcinogenesis, and teratogenesis were not mentioned in the included studies. No statistical difference was found in gastrointestinal discomfort reported as the most common adverse reaction (P>0.05).


#### 3.4.2. Outcomes of Animal Studies

(1) Survive Rate. A meta-analysis of 4 studies [13, 54, 57, 58] showed that AM induces a significant improvement in the survive rate of VM animals, compared with the control group (n=227, RR 1.58, 95% CI [1.29 to 1.92], P<0.0001; heterogeneity: χ2=1.08, df=3 (P=0.78); I2=0%, Figure 8).Figure 8
The forest plot: effects of AM for increasing the survive rate of VM animals.(2) Cardiac Pathology. Cardiac pathology was reported in 15 studies [13, 47–55, 57–61]. Among them, 12 studies [13, 47–51, 53–55, 59–61] calculated cardiac pathological score with reference to the method proposed by Siasos et al. [62]. Meta-analysis of these studies showed significant effects of AM on reducing cardiac pathological score in animals with VM (n=246, MD −1.18, 95% CI [−1.31 to −1.05], P<0.0001; heterogeneity: χ2=17.70, df=11 (P=0.09); I2=38%, Figure 9). Among other studies, AM treatment significantly promoted the growth of cardiac fibroblasts in 1 study [52]. Astragalus inhibited the hypertrophy of cardiomyocyte in 1 study [58]. Astragalus inhibited the infiltration of inflammatory cell in 1 study [57].Figure 9
The forest plot: effects of AM for decreasing cardiac pathological score compared with the control group (animal studies).(3) Cardiac Enzymes and Cardiac Troponin. Meta-analysis of 3 studies [47, 49, 61] indicated significant effects of AM on reducing CK-MB in VM animals compared with control group (n=63, SMD −1.65, 95% CI [−2.33 to −0.98], P<0.00001; heterogeneity: χ2=25.62, df=2 (P<0.00001); I2=92%). After sensitivity analyses, we removed 1 study [47] that used AM at a dose of 0.4 ml/g. Meta-analysis of 2 studies [49, 61] showed significant effects of AM on reducing CK-MB (n=39, SMD −1.20, 95% CI [−1.90 to −0.50], P<0.00001; heterogeneity: χ2=0.75, df=1 (P=0.39); I2=0%, Figure 10). Meta-analysis of 2 studies [57, 61] showed significant effects of AM on decreasing LDH compared with the control group (n=42, SMD −1.04, 95% CI [−1.71 to −0.38], P<0.00001; heterogeneity: χ2=0.01, df=1 (P=0.91); I2=0%, Figure 11). Meta-analysis of 3 studies [13, 47, 50] showed significant effects of AM on decreasing cTnI compared with the control group (n=68, SMD −2.39, 95% CI [−3.13 to −1.65], P<0.00001; heterogeneity: χ2=25.23, df=2 (P<0.00001); I2=92%, Figure 12). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in cTnI.Figure 10
The forest plot: effects of AM for decreasing CK-MB compared with the control group (animal studies).Figure 11
The forest plot: effects of AM for decreasing LDH compared with the control group (animal studies).Figure 12
The forest plot: effects of AM for decreasing cTnI compared with the control group (animal studies).(4) Cardioprotective Mechanisms. Meta-analysis of 3 studies [49, 53, 56] showed significant effects of AM on decreasing TNF-α compared with the control group in VM animal (n=84, SMD −2.02, 95% CI [−2.57 to −1.48], P<0.00001; heterogeneity: χ2=0.54, df=2 (P=0.77); I2=0%, Figure 13); 1 study [52] for reducing IL-2, IL-8, and IL-18 (P<0.05); 1 study [51] for reducing MCP-1 (P<0.05); 1 study [50] for reducing MIP-2 (P<0.05); 1 study [57] for reducing MDA (P<0.05) and increasing SOD (P<0.05); 1 study [55] for reducing the expression of CAR (P<0.05); 1 study [48] for reducing Cav-3 and Smad3 (P<0.05); 1 study [13] for reducing ET-1, ANP, and ETR Bmax (P<0.05) and increasing the activity of SERCA (P<0.05), and 1 study [60] for reducing the expression of Fas and FasL (P<0.05).Figure 13
The forest plot: effects of AM for decreasing TNF-α compared with the control group (animal studies).


### 3.5. Subgroup Analysis

The potential confounding factors (including age of animals, varying methods of administration, varying doses of AM, and various durations of treatment) that may increase the heterogeneity of outcome measures were explored using stratified analysis of cardiac pathological score. In the subgroup analysis of age of Balb/c mice, the effect size of the model used mature mice (≥6 weeks) showed better results than immature mice (<6 weeks) (SMD −1.40 vs. SMD −0.97,P=0.009, Figure 14(d)), and the heterogeneity of two groups decreased obviously. No difference was seen between the intraperitoneal injection group and oral gavage group (SMD −1.01 vs. SMD −1.28, P=0.06, Figure 14(c)). The heterogeneity of the two groups decreased insignificantly. In the subgroup analysis of durations of treatment, the longer period of AM treatment (>10 days) showed better effect size than the shorter treatment (≤10 days) (SMD −1.28 vs. SMD −1.01, P=0.05, Figure 14(a)), and the heterogeneity of the longer period group decreased significantly. No difference was seen between the high dose of AM group (≥10 g/kg) and low-dose group (<10 g/kg) (SMD −1.08 vs. SMD −1.15, P=0.15, Figure 14(b)), and the heterogeneity of two groups decreased insignificantly.Figure 14
Effect of AM on cardiac pathological score in subgroups. (a) Duration of treatment; (b) AM dose; (c) induction type; (d) age of animals.#P>0.05 vs. control groups; ∗P≤0.05 vs. control groups.
(a)(b)(c)(d)


## 3.1. Study Selection

For clinical studies, a total of 173 studies were extracted from initially collected 861 studies after scanning the titles and abstracts. Detailed inspection was performed to remaining full-text studies; 145 studies were excluded according to the inclusion and exclusion criteria. For animal studies, a total of 142 studies were extracted from initially collected 762 studies after scanning the titles and abstracts. Detailed inspection was performed to remaining full-text studies; 126 studies were excluded according to the inclusion and exclusion criteria. Finally, 28 randomized controlled clinical trials and 16 animal studies were included. The detailed search process was shown in Figure1.Figure 1
Summary of the process for identifying candidate studies. (a) Search strategy for clinical studies. (b) Search strategy for animal studies.
(a)(b)


## 3.2. Characteristics of Included Studies

### 3.2.1. Clinical Studies

The overall characteristics of included clinical studies are generalized in Table1. All included studies were RCTs published in Chinese from 2006 to 2019. Among them, 9 studies [19–27] are involved in adult with VM and 19 studies [28–46] in children with VM. With regard to the information of the participants in the experiment, a total of 1276 subjects were included in the intervention group, while a total of 1246 subjects in the control group. The baseline of the two groups was comparable. Twenty-one studies [19–22, 24, 26, 27, 29, 31, 33–35, 37, 39, 42–46] implemented the dose gradient of AM ranged from 5 ml•d−1 to 200 ml•d−1 by intravenous drip infusion administration. In addition, 0.5 ml•kg−1•d−1 Astragalus membranaceus injection (AI) was administered by intravenous drip infusion in 1 study [30], 1 ml•kg−1•d−1 in 1 study [36], 2 ml•kg−1•d−1 in 1 study [28], 2 g•kg−1•d−1 in 1 study [41], and 20 g•kg−1•d−1 in 1 study [25]; and the oral dosage of AM granule was adjusted according to age (2 g/d (age≤2Y), 3 g/d (2Y<age≤4Y), 4 g/d (4Y<age≤6Y), and 8 g/d (age>6Y)) and was reported in 2 studies [32, 38]. Except 1 study [37] reported that it only contrasted the curative effect of AI and placebo without additional treatment, the remaining 27 studies reported that the intervention group and the control group were given basic treatment (including antivirus, anti-infection, antiarrhythmia, and nourishing myocardium), and AI or granules were added to the intervention group. Detailed information on AM in each clinical study is displayed in Table 2. As for follow-up period, 18 studies [20, 22–25, 27–30, 33–38, 40, 42, 43, 45] lasted 2 weeks, 7 studies [21, 26, 31, 32, 41, 44, 46] lasted 4 weeks, 1 study [19] lasted 6 weeks, and 1 study [39] lasted 46 days. Creatine kinase (CK) was utilized as primary outcome measure in 11 studies [22, 23, 25, 28–31, 35, 37, 41, 45]; creatine kinase isoenzyme (CK-MB) in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41]; lactate dehydrogenase (LDH) in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45]; glutamic pyruvate transaminase (AST) in 7 studies [19, 25, 27, 38, 41, 42, 45]; and cardiac troponin iroponin I (cTnI) in 8 studies [21, 23, 26, 28–30, 35, 37]. Ejection fraction (EF) was utilized as a primary outcome measure in 1 study [20], and none of the included studies were involved in mortality and major cardiovascular events. The clinical efficacy of AM in the treatment of VM was utilized as a secondary outcome measure in 26 studies [19–23, 25–28, 30–46] and the adverse reactions in 10 studies [19, 26–29, 32, 33, 36, 37, 39].Table 1
The characteristic of clinical studies.
Study (years)Number (n = male/female); mean age (years); course of disease (days)TreatmentsDuration of treatmentAdverse reactionsOutcome indexIntergroup differencesExperimental groupControl groupExperimental groupControl groupDu 201948 (25/23)48 (26/22)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + sodium creatine phosphate for injection (1 g, qd)2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.81±2.247.63±2.16NMNMLi et al. 201946 (25/21)46 (26/20)By intravenous drip infusion of AM injection (2 ml/kg, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(5) TNF-α(6) IL-6(7) Effect of arrhythmia(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.055.67±1.825.83±1.72NMNMQi et al. 201960 (NM)60 (NM)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS500ml+basic treatmentAdenosine disodium triphosphate, coenzyme A and insulin for injection20mg,qd+fructose sodium diphosphate injection (5 g, bid)4 weeksN(1) Effective rate(2) hs-CRP(3) CK-MB(4) cTnI(5) TNF-β(6) IL-10(7) IL-17(8) IL-21(9) miR-146b(10) miR-155(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.05(10) P<0.05NMNMNMNMZhang et al. 201946 (22/24)45 (20/25)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS200ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + Inosine injection + fructose 1,6-diphosphate injection2 weeksN(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) CD4+/CD8+(6) EF(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.0536.12±5.8735.52±5.47NMNMZheng 201945 (21/24)44 (23/21)By intravenous drip infusion of AM injection (20 ml, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + trimetazidine6 weeksY(1) Recover time of clinical symptoms(2) Recovery time of arrhythmia(3) CK-MB(4) AST(5) LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0548.47±15.2549.15±16.1815.11±3.2516.01±3.31Liu et al. 201843 (20/23)43 (24/19)By intravenous drip infusion of AM injection (0.5 ml/kg, qd) in 5% GS250ml+basic treatmentAntiviral drugs + vitamin C + fructose + coenzyme Q10 + creatine phosphate injection (1.0 g, qd)2 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.057.36±1.487.74±1.65NMNMGui 201767 (34/33)67 (35/32)By oral administration of AM granule (age≤2 years 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentVitamin C + energy mixture injection + vitamin E + coenzyme Q + coenzyme A4 weeksY(1) Effective rate(1)P<0.055.4±0.55.7±0.3NMNMZhang et al. 2017B36 (20/16)36 (14/22)By intravenous drip infusion of AM injection (10 ml, qd) in 5% GS + basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + coenzyme Q104 weeksN(1).Effective rate(2) CK(3) CK-MB(4) TNF-α(5) IL-10(6) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.055.29±2.915.38±2.86NMNMZhou 201750 (26/24)50 (28/22)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q1015 daysN(1) Effective rate(2) CK(3) CK-MB(4)LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0535.9±2.736.4±3.4NMNMLi et al. 2016A34 (21/13)34 (19/15)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentVitamin C + vitamin E + coenzyme Q10 + energy mixture injection2 weeksN(1) Effective rate(2) INF-γ(3) IL-4(4) INF-γ/IL-4(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.058.54±4.389.14±5.266.21±3.175.26±2.79Xing 201645 (29/16)5.4±1.714.7±3.241 (28/13)5.1±1.615.1±3.4By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q103 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(6) CD3+(7) CD4+(8) CD8+(1)P<0.01(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.05(8) P<0.05Wu 201647 (21/26)47 (24/23)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + energy mixture injection2 weeksN(1) Effective rate(2) LDH(3) cTnI(4) CD3+(5) CD4+(6) CD8+(7) NK(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.0126.7±10.126.4±10.5NMNMWu et al. 201640 (24/16)40 (22/18)By intravenous drip infusion of AM injection (10-20 ml, qd) in NS50ml+basic treatmentAntiviral drugs + fructose2 weeksY(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) NK(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.48±1.406.44±1.432.13±0.682.11±0.66Gao 201560 (27/33)60 (25/35)By intravenous drip infusion of AM injection (20 g, qd) in 5% GS500ml+basic treatmentPolarization liquid + vitamin C + coenzyme Q102 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0538.5±7.237.4±7.031.2±6.932.1±8.0Lou 201548 (34/14)48 (25/23)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS 250 mlPolarization liquid2 weeksY(1) Effective rate(2) TNF-α(3) INF-8(4) INF-6(5) CK(6) CK-MB(7) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.056.01±1.25.8±1.5NMNMTao 201539 (22/17)39 (24/15)By intravenous drip infusion of AM injection (1 ml/kg, qd) in 5% GS100ml+basic treatmentAntiviral drugs (ribavirin) + coenzyme A + ATP + vitamin C15 daysY(1) Effective rate(2) Recover time of clinical symptoms(3) Recover time of clinic syndrome myocardial enzyme(1)P<0.05(2) P<0.05(3) P<0.056.2±2.46.6±2.77.5±7.67.2±7.3Zhao et al. 201589 (51/38)89 (44/45)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q10 + inosine tablets + polarization liquid2 weeksN(1) Effective rate(2) SOD(3) MDA(4) GST(5) NO(6) TNF-α(7) INF-γ(8) IL-8(9) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.0529.4±11.830.1±12.7NMNMBan 201434 (20/14)34 (18/16)By intravenous drip infusion of AM injection (2 g/kg, qd) in 5% GS250ml+basic treatmentCoenzyme Q10 + ATP + vitamin C4 weeksN(1) CK(2) CK-MB(3) LDH(4) AST(5) α-HBDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.058±2.019±1.28NMNMWang et al. 201430 (16/14)30 (18/12)By intravenous drip infusion of AM injection (20 ml, qd) in 10% GS250ml+basic treatmentAntiviral drugs (acyclovir) + vitamin C + coenzyme A46 daysY(1) Effective rate(1)P<0.059.3±2.812.1±2.2NMNMLiang 201425 (14/11)25 (13/12)By intravenous drip infusion of AM injection (10-20 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q104 weeksN(1) Effective rate(2) SOD(3) MDA(4) NO(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.9±3.68.1±3.216.2±2.514.1±2.3Kang 201443 (22/21)43 (21/22)By intravenous drip infusion of AM injection (30 ml, qd) in 10% GS 250 mlNM15 daysN(1) Effective rate(2) Effect of arrhythmia(1)P<0.05(2) P<0.05NMNMNMNMZhang 201457 (32/25)56 (32/24)By oral administration of AM granule (age≤2 years, 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentAntiviral drugs (ribavirin) + fructose + coenzyme Q10 + vitamin C + gamma globulin2 weeksN(1) Effective rate(2) CK-MB(3) LDH(4) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.053.7±1.53.8±1.57.4±0.87.3±0.8Liu et al. 201332 (18/14)32 (20/12)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentNM2 weeksN(1) Effective rate(2) IL-23(3) IL-17(4) Th17 cell(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.059.1±5.18.7±4.56.2±3.15.2±2.8Zhang et al. 201334 (17/17)34 (17/17)By intravenous drip infusion of AM injection (50 ml, qd) in 5% GS250ml+basic treatmentEnergy mixture injection + vitamin C + coenzyme Q10 + polarization liquid2 weeksN(1) Effective rate(2) CK-MB(3) ESR(4) AST(5) ALT(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05NMNMNMNMWang 201235 (18/17)35 (20/15)By intravenous drip infusion of AM injection (50 ml, qd) + basic treatmentAntiviral drugs + vitamin C + coenzyme Q10 + polarization liquid + Trimetazidine4 weeksY(1) Effective rate(2) Arrhythmia(3) cTnI(4) Cardiac function(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0555±1160±953±1755±16Dong 201160 (34/26)50 (28/22)By intravenous drip infusion of AM injection (5-20 ml, qd) + basic treatmentAntiviral drugs (ribavirin) + vitamin C + fructose + energy mixture injection30 daysN(1) Effective rate(2) Recovery rate of CK-MB(3) Recovery rate of CK(4) Recovery rate of LDH(5) Recovery rate of AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.56.9NMNMHu 200950 (26/24)50 (27/23)By intravenous drip infusion of AM injection (60 ml, bid) in 5% GS250ml+basic treatmentCoenzyme Q10 + polarization liquid2 weeksY(1) Effective rate(2) Effect of arrhythmia(3) AST(4) CK-MB(5) LDH(6) cTnI(7) NK(8) TNF-α(9) IL-1(10) IL-6(1)P<0.05(2) P<0.05(3) P>0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P>0.05(9) P<0.05(10) P>0.0538±10.135±9.84±0.7 months5±0.6 monthsZhang et al. 2006B33 (20/13)20 (14/6)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + vitamin E + energy mixture injection2 weeksN(1) Effective rate(2) CK(3) AST(4) LDH(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.052±112±11NMNMNote:α-HBDH: α-hydroxybutyric dehydrogenase; hs-CRP: hypersensitive C-reactive protein; miR: microRNA; ALT: alanine aminotransferase; AM: Astragalus membranaceus; AST: aspartate aminotransferase; ATP: adenosine triphosphate; Bid: bis in die; cTnI: cardiac troponin I; CD: cluster of differentiation; CK: creatine kinase; CK-MB: creatine kinase isoenzyme; EF: ejection fraction; ESR: erythrocyte sedimentation rate; GS: glucose injection; GST: glutathione transferase; IL: interleukin; INF-γ: interferon-γ; LDH: lactic dehydrogenase; MDA: malondialdehyde; N: no; NK: natural killer cell; NM: not mentioned; NO: nitric oxide; NS: normal saline; Qd: quaque die; SOD: superoxide dismutase; Th: T helper cell; TNF: tumor necrosis factor; Y: yes.Table 2
Information of AM of clinical study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedDu 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Li et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z19993151Qi et al. 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Zhang et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z20003189Zheng 2019InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Liu et al. 2018InjectionUnknownUnknownUnknownGui 2017GranuleUnknownUnknownUnknownZhang et al. 2017BInjectionUnknownUnknownUnknownZhou 2017InjectionUnknownUnknownUnknownLi et al. 2016AInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094Xing 2016InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLBatch number: 20120829Wu 2016InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Wu et al. 2016InjectionUnknownUnknownUnknownGao 2015InjectionUnknownUnknownUnknownLou 2015InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z33020178Tao 2015InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Zhao et al. 2015InjectionHarbin Shengtai Biopharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020820Ban 2014InjectionUnknownUnknownUnknownWang et al. 2014InjectionDali Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z53021585Liang 2014InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLBatch number: 100226Kang 2014InjectionUnknownUnknownUnknownZhang 2014GranuleUnknownUnknownUnknownLiu et al. 2013InjectionChengdu Di’ao Jiuhong pharmaceutical factory2 g/mLBatch number: 0210094Zhang et al. 2013InjectionUnknownUnknownUnknownWang 2012InjectionUnknownUnknownUnknownDong 2011InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLBatch number: 020213210901082, 0506013Hu 2009InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13021000Zhang et al. 2006BInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094


### 3.2.2. Animal Studies

The overall characteristics of the included animal study are generalized in Table3. A total of 15 Chinese studies [47–61] and 1 English study [13] on AM for VM published between 2002 and 2017 were included. All studies are involved in 634 experimental animals. Among them, male Balb/c mice were used in 13 studies [13, 47, 49–51, 53, 54, 56–61], female Balb/c mice in 1 study [52], Balb/c mice without mentioning gender in 1 study [55], and male/female SD rats in 1 study [48]. All models of acute VM were established by intraperitoneal injection of a solution containing coxsackievirus B3 (CVB3) virus. Twelve studies [13, 48–51, 53, 56–61] implemented the dose gradient of AM ranged from 2.2 mg•kg−1•d−1 to 90 g•kg−1•d−1. In addition, 1 study [54] used the dosage of AM with 0.4 mg•d−1, 2 studies [52, 55] used 0.4 g•d−1, and 1 study [47] used 0.4 ml•g−1•d−1. Intragastric administration was adopted in 7 studies [13, 53–56, 59, 61] and intraperitoneal injection in 9 studies [47–52, 57, 58, 60]. All included studies reported that the intervention group received AM as monotherapy, while the control group was treated with the same volume of normal saline or nonfunctional liquid therapy or placebo. Detailed information of AM in each animal study is displayed in Table 4. The survival rate of animals was utilized as the primary outcome measure in 4 studies [13, 54, 57, 58], the changes of cardiac pathology or cardiac pathological score in 15 studies [13, 47–55, 57–61], cTnI in 3 studies [13, 47, 50], CK-MB in 3 studies [47, 49, 61], LDH in 2 studies [57, 61], AST in 1 study [57], and none of the included studies involved in the indexes of cardiac function under B-ultrasound. Among secondary outcome indicators for the study of mechanism, tumor necrosis factor (TNF-α) was reported in 4 studies [49, 53, 54, 56]; interleukin-2 (IL-2), interleukin-8 (IL-8), and interleukin-18 (IL-18) in 1 study [52]; nuclear chemokine-1 (MCP-1) in 1 study [51]; macrophage inflammatory protein-2 (MIP-2) in 1 study [50]; superoxide dismutase (SOD) and malondialdehyde (MDA) in 1 study [57]; Caveolin-3 (Cav-3) and Smad family member 3 (Smad3) in 1 study [48]; coxsackievirus and adenoviral receptor (CAR) in surface myocardium in 1 study [55]; sarco endoplasmic reticulum calcium adenosine triphosphatase (SERCA), endothelin-1 (ET-1) and the maximum binding capacity of endothelin receptor maximum binding capacity (ETR Bmax) in 1 study [13]; the replication level of CVB3 in 1 study [59]; the changes of Fas/FasL gene expression in cardiomyocytes in 1 study [60]; and the atrial natriuretic peptide (ANP) in 1 study [13].Table 3
The characteristic of animal studies.
Study (years)Species (age; sex; number = experimental/control)WeightModel (method)Experimental groupControl groupOutcome indexIntergroup differencesZhang et al. 2017ABalb/c mice (4-6 weeks; male; 12/12)16-18 gBy intraperitoneal injection of culture medium containing 1000 PFU/ml CVB3 virus (0.4 ml)By intraperitoneal injection of AM injection (0.4 ml/g, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml/g, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) CK-MB(1)P<0.05(2) P<0.01(3) P<0.01Li et al. 2016BSD rats (7-9 weeks; male/female; 15/15)182±36gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (1.68 g/kg, qd) for 15 d after establishing modelBy intraperitoneal injection of normal saline (20 ml/kg, qd) for 15 d after establishing model(1) Changes of cardiac pathology(2) Caveolin-3(3) Smad-3(1)P<0.05(2) P<0.01(3) P<0.05Jiang 2013Balb/c mice (4-6 weeks; NM; 12/12)NMBy intraperitoneal injection of culture medium containing 2000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 7 d after establishing model(1) Changes of cardiac pathology(2) CK-MB(3) TNF-α(1)P<0.01(2) P<0.01(3) P<0.01Wang et al. 2011Balb/c mice (4 weeks; male; 15/15)12-16 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) MIP-2 mRNA(4) MIP-2(1)P<0.01(2) P<0.05(3) P<0.01(4) P<0.01Cai et al. 2009Balb/c mice (6-8 weeks; male; 20/20)18-22 gBy intraperitoneal injection of culture medium containing 1000 TCID50 CVB3 virus (0.15 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) MCP-1 mRNA(3) MCP-1(1)P<0.05(2) P<0.01(3) P<0.05Zhang et al. 2009Balb/c mice (6-8 weeks; female; 20/20)NMBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (0.4 g, qd) for 21 d after establishing modelBy intraperitoneal injection of normal saline (0.2 ml, qd) for 21 d after establishing model(1) Changes of cardiac pathology(2) IL-2(3) IL-8(4) IL-18(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2007Balb/c mice (5 weeks; NM; 40/40)15-16 gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.4 g, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.3 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Coxsackievirus and adenovirus receptor mRNA(1)P<0.01(2) P<0.01Wu et al. 2007Balb/c mice (4 weeks; male; 20/20)14±2gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.2 ml)By oral gavage of AM oral liquid (0.2 mg, bid) for 10 d after establishing modelBy oral gavage of normal saline (0.2 ml, bid) for 10 d after establishing model(1) Changes of cardiac pathology(2) TNF-α mRNA(3) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05Yao et al. 2007Balb/c mice (5 weeks; male; 20/20)16-20 gBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (30 g/kg, qd) for 5 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml, qd) for 5 d after establishing model(1) Changes of cardiac pathology(2) TNF-α(1)P<0.05(2) P<0.05Chen et al. 2006Balb/c mice (3 weeks; male; 36/31)12-15 gBy intraperitoneal injection of culture medium containing 20000 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (2.2 mg/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) SERCA activity(4) ETR maximum binding capacity(5) ETR equilibrium dissociation constant(6) ET-1(7) ANP(8) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05Zhang et al. 2006ABalb/c mice (4 weeks; male; 30/30)NMBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM granule (30 g/kg, qd) for 5 d after establishing modelBy oral gavage of normal saline for 5 d after establishing model(1) Cardiomyocyte apoptosis rate(2) TNF-α(1)P<0.05(2) P<0.05Guan et al. 2005Balb/c mice (NM; male; 8/6)17.5±1.2gBy intraperitoneal injection of culture medium containing 400 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (90 g/kg, qd) for 9 d after establishing modelBy intraperitoneal injection of normal saline for 9 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(3) AST(4) LDH(5) MDA(6) SOD(7) Affect of electrocardiogram(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05Liu et al. 2004Balb/c mice (45 weeks; male; 50/50)14-16 gBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of phosphate buffered solutions (0.2 ml, qd) for 7 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(1)P<0.05(2) P<0.05Liu et al. 2003Balb/c mice (4-6 weeks; male; 12/12)NMBy intraperitoneal injection of culture medium containing1×109 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline for 7 d after establishing model(1) Changes of cardiac pathology(2) Apoptotic index(3) Fas(4) FasL(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2003Balb/c mice (6-8 weeks; male; 20/20)16-18 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.78 g/kg, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.5 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Virus isolation positive rate(1)P<0.01(2) P>0.05Liu et al. 2002Balb/c mice (NM; male; 10/11)12.8±1.0gBy intraperitoneal injection of culture medium containing9×109 PFU/ml CVB3 virus (0.4 ml)By oral gavage of AM oral liquid (10 g/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) HW/BW ratios(2) Changes of cardiac pathology(3) LDH(4) CK-MB(1)P<0.05(2) P<0.05(3) P<0.01(4) P<0.05Note: d: day; AM: Astragalus membranaceus; ANP: atrial natriuretic peptide; AST: aspartate aminotransferase; Bid: bis in die; cTnI: cardiac troponin I; CK-MB: creatine kinase isoenzyme; CVB3: coxsackievirus B3; ET: endothelin; ETR: endothelin receptor; HW/BW: heart weight/body weight; IL: interleukin; LDH: lactic dehydrogenase; MCP: monocyte chemoattractant protein; MDA: malondialdehyde; MIP: macrophage inflammatory protein; NM: not mentioned; PFU: plaque-forming unit; Qd: quaque die; SERCA: sarco endoplasmic reticulum calcium adenosine triphosphatase; Smad: small mothers against decapentaplegic; SOD: superoxide dismutase; TCID50: median tissue culture infective dose; TNF-α: tumor necrosis factor-α.Table 4
Information of AM of animal study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedZhang et al. 2017AInjectionUnknownUnknownUnknownLi et al. 2016BGranuleNanjing Tongrentang Pharmaceutical Co., Ltd.UnknownBatch number: 140604Jiang 2013InjectionFuda Pharmaceutical Co., Ltd.2 g/mLBatch number: 000617Wang et al. 2011InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Cai et al. 2009InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Zhang et al. 2009InjectionHugang Xinya Pharmaceutical Industry (Yangzhou) Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z32021256Li et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownTraditional Chinese patented medicine WY: Z20003380Wu et al. 2007Oral liquidUnion Hospital affiliated Huazhong University of Science and Technology1 g/LBatch number: 020926Yao et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Chen et al. 2006InjectionFuda Pharmaceutical Co., Ltd.2 g/mLUnknownZhang et al. 2006AGranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Guan et al. 2005InjectionShanghai Tiansheng Pharmaceutical Chemical Industry Research Institute12 g/mLBatch number: 20020108Liu et al. 2004InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLUnknownLiu et al. 2003InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLUnknownLi et al. 2003Oral liquidUnknown2 g/mLUnknownLiu et al. 2002Oral liquidUnknown1 g/mLUnknown


## 3.2.1. Clinical Studies

The overall characteristics of included clinical studies are generalized in Table1. All included studies were RCTs published in Chinese from 2006 to 2019. Among them, 9 studies [19–27] are involved in adult with VM and 19 studies [28–46] in children with VM. With regard to the information of the participants in the experiment, a total of 1276 subjects were included in the intervention group, while a total of 1246 subjects in the control group. The baseline of the two groups was comparable. Twenty-one studies [19–22, 24, 26, 27, 29, 31, 33–35, 37, 39, 42–46] implemented the dose gradient of AM ranged from 5 ml•d−1 to 200 ml•d−1 by intravenous drip infusion administration. In addition, 0.5 ml•kg−1•d−1 Astragalus membranaceus injection (AI) was administered by intravenous drip infusion in 1 study [30], 1 ml•kg−1•d−1 in 1 study [36], 2 ml•kg−1•d−1 in 1 study [28], 2 g•kg−1•d−1 in 1 study [41], and 20 g•kg−1•d−1 in 1 study [25]; and the oral dosage of AM granule was adjusted according to age (2 g/d (age≤2Y), 3 g/d (2Y<age≤4Y), 4 g/d (4Y<age≤6Y), and 8 g/d (age>6Y)) and was reported in 2 studies [32, 38]. Except 1 study [37] reported that it only contrasted the curative effect of AI and placebo without additional treatment, the remaining 27 studies reported that the intervention group and the control group were given basic treatment (including antivirus, anti-infection, antiarrhythmia, and nourishing myocardium), and AI or granules were added to the intervention group. Detailed information on AM in each clinical study is displayed in Table 2. As for follow-up period, 18 studies [20, 22–25, 27–30, 33–38, 40, 42, 43, 45] lasted 2 weeks, 7 studies [21, 26, 31, 32, 41, 44, 46] lasted 4 weeks, 1 study [19] lasted 6 weeks, and 1 study [39] lasted 46 days. Creatine kinase (CK) was utilized as primary outcome measure in 11 studies [22, 23, 25, 28–31, 35, 37, 41, 45]; creatine kinase isoenzyme (CK-MB) in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41]; lactate dehydrogenase (LDH) in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45]; glutamic pyruvate transaminase (AST) in 7 studies [19, 25, 27, 38, 41, 42, 45]; and cardiac troponin iroponin I (cTnI) in 8 studies [21, 23, 26, 28–30, 35, 37]. Ejection fraction (EF) was utilized as a primary outcome measure in 1 study [20], and none of the included studies were involved in mortality and major cardiovascular events. The clinical efficacy of AM in the treatment of VM was utilized as a secondary outcome measure in 26 studies [19–23, 25–28, 30–46] and the adverse reactions in 10 studies [19, 26–29, 32, 33, 36, 37, 39].Table 1
The characteristic of clinical studies.
Study (years)Number (n = male/female); mean age (years); course of disease (days)TreatmentsDuration of treatmentAdverse reactionsOutcome indexIntergroup differencesExperimental groupControl groupExperimental groupControl groupDu 201948 (25/23)48 (26/22)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + sodium creatine phosphate for injection (1 g, qd)2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.81±2.247.63±2.16NMNMLi et al. 201946 (25/21)46 (26/20)By intravenous drip infusion of AM injection (2 ml/kg, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs2 weeksY(1) Effective rate(2) CK(3) CK-MB(4) cTnI(5) TNF-α(6) IL-6(7) Effect of arrhythmia(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.055.67±1.825.83±1.72NMNMQi et al. 201960 (NM)60 (NM)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS500ml+basic treatmentAdenosine disodium triphosphate, coenzyme A and insulin for injection20mg,qd+fructose sodium diphosphate injection (5 g, bid)4 weeksN(1) Effective rate(2) hs-CRP(3) CK-MB(4) cTnI(5) TNF-β(6) IL-10(7) IL-17(8) IL-21(9) miR-146b(10) miR-155(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.05(10) P<0.05NMNMNMNMZhang et al. 201946 (22/24)45 (20/25)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS200ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + Inosine injection + fructose 1,6-diphosphate injection2 weeksN(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) CD4+/CD8+(6) EF(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.0536.12±5.8735.52±5.47NMNMZheng 201945 (21/24)44 (23/21)By intravenous drip infusion of AM injection (20 ml, qd) in NS250ml+basic treatmentAntiviral drugs + nutritional myocardial drugs + trimetazidine6 weeksY(1) Recover time of clinical symptoms(2) Recovery time of arrhythmia(3) CK-MB(4) AST(5) LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0548.47±15.2549.15±16.1815.11±3.2516.01±3.31Liu et al. 201843 (20/23)43 (24/19)By intravenous drip infusion of AM injection (0.5 ml/kg, qd) in 5% GS250ml+basic treatmentAntiviral drugs + vitamin C + fructose + coenzyme Q10 + creatine phosphate injection (1.0 g, qd)2 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.057.36±1.487.74±1.65NMNMGui 201767 (34/33)67 (35/32)By oral administration of AM granule (age≤2 years 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentVitamin C + energy mixture injection + vitamin E + coenzyme Q + coenzyme A4 weeksY(1) Effective rate(1)P<0.055.4±0.55.7±0.3NMNMZhang et al. 2017B36 (20/16)36 (14/22)By intravenous drip infusion of AM injection (10 ml, qd) in 5% GS + basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + coenzyme Q104 weeksN(1).Effective rate(2) CK(3) CK-MB(4) TNF-α(5) IL-10(6) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.055.29±2.915.38±2.86NMNMZhou 201750 (26/24)50 (28/22)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q1015 daysN(1) Effective rate(2) CK(3) CK-MB(4)LDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0535.9±2.736.4±3.4NMNMLi et al. 2016A34 (21/13)34 (19/15)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentVitamin C + vitamin E + coenzyme Q10 + energy mixture injection2 weeksN(1) Effective rate(2) INF-γ(3) IL-4(4) INF-γ/IL-4(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.058.54±4.389.14±5.266.21±3.175.26±2.79Xing 201645 (29/16)5.4±1.714.7±3.241 (28/13)5.1±1.615.1±3.4By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q103 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) cTnI(6) CD3+(7) CD4+(8) CD8+(1)P<0.01(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.05(8) P<0.05Wu 201647 (21/26)47 (24/23)By intravenous drip infusion of AM injection (20 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (recombinant human interferonα2b injection) + vitamin C + energy mixture injection2 weeksN(1) Effective rate(2) LDH(3) cTnI(4) CD3+(5) CD4+(6) CD8+(7) NK(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.01(5) P<0.01(6) P<0.01(7) P<0.0126.7±10.126.4±10.5NMNMWu et al. 201640 (24/16)40 (22/18)By intravenous drip infusion of AM injection (10-20 ml, qd) in NS50ml+basic treatmentAntiviral drugs + fructose2 weeksY(1) Effective rate(2) CD3+(3) CD4+(4) CD8+(5) NK(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.48±1.406.44±1.432.13±0.682.11±0.66Gao 201560 (27/33)60 (25/35)By intravenous drip infusion of AM injection (20 g, qd) in 5% GS500ml+basic treatmentPolarization liquid + vitamin C + coenzyme Q102 weeksN(1) Effective rate(2) CK(3) CK-MB(4) LDH(5) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.0538.5±7.237.4±7.031.2±6.932.1±8.0Lou 201548 (34/14)48 (25/23)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS 250 mlPolarization liquid2 weeksY(1) Effective rate(2) TNF-α(3) INF-8(4) INF-6(5) CK(6) CK-MB(7) cTnI(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.056.01±1.25.8±1.5NMNMTao 201539 (22/17)39 (24/15)By intravenous drip infusion of AM injection (1 ml/kg, qd) in 5% GS100ml+basic treatmentAntiviral drugs (ribavirin) + coenzyme A + ATP + vitamin C15 daysY(1) Effective rate(2) Recover time of clinical symptoms(3) Recover time of clinic syndrome myocardial enzyme(1)P<0.05(2) P<0.05(3) P<0.056.2±2.46.6±2.77.5±7.67.2±7.3Zhao et al. 201589 (51/38)89 (44/45)By intravenous drip infusion of AM injection (20-30 ml, qd) in 5% GS250ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + coenzyme Q10 + inosine tablets + polarization liquid2 weeksN(1) Effective rate(2) SOD(3) MDA(4) GST(5) NO(6) TNF-α(7) INF-γ(8) IL-8(9) IL-6(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05(9) P<0.0529.4±11.830.1±12.7NMNMBan 201434 (20/14)34 (18/16)By intravenous drip infusion of AM injection (2 g/kg, qd) in 5% GS250ml+basic treatmentCoenzyme Q10 + ATP + vitamin C4 weeksN(1) CK(2) CK-MB(3) LDH(4) AST(5) α-HBDH(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.058±2.019±1.28NMNMWang et al. 201430 (16/14)30 (18/12)By intravenous drip infusion of AM injection (20 ml, qd) in 10% GS250ml+basic treatmentAntiviral drugs (acyclovir) + vitamin C + coenzyme A46 daysY(1) Effective rate(1)P<0.059.3±2.812.1±2.2NMNMLiang 201425 (14/11)25 (13/12)By intravenous drip infusion of AM injection (10-20 ml, qd) in 5% GS100ml+basic treatmentAntiviral drugs + vitamin C + coenzyme Q104 weeksN(1) Effective rate(2) SOD(3) MDA(4) NO(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.057.9±3.68.1±3.216.2±2.514.1±2.3Kang 201443 (22/21)43 (21/22)By intravenous drip infusion of AM injection (30 ml, qd) in 10% GS 250 mlNM15 daysN(1) Effective rate(2) Effect of arrhythmia(1)P<0.05(2) P<0.05NMNMNMNMZhang 201457 (32/25)56 (32/24)By oral administration of AM granule (age≤2 years, 1 g, bid; 2<age≤4 years, 1.5 g, bid; 4<age≤6 years, 2 g, bid; age>6 years, 4 g, bid) + basic treatmentAntiviral drugs (ribavirin) + fructose + coenzyme Q10 + vitamin C + gamma globulin2 weeksN(1) Effective rate(2) CK-MB(3) LDH(4) AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.053.7±1.53.8±1.57.4±0.87.3±0.8Liu et al. 201332 (18/14)32 (20/12)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS100ml+basic treatmentNM2 weeksN(1) Effective rate(2) IL-23(3) IL-17(4) Th17 cell(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.059.1±5.18.7±4.56.2±3.15.2±2.8Zhang et al. 201334 (17/17)34 (17/17)By intravenous drip infusion of AM injection (50 ml, qd) in 5% GS250ml+basic treatmentEnergy mixture injection + vitamin C + coenzyme Q10 + polarization liquid2 weeksN(1) Effective rate(2) CK-MB(3) ESR(4) AST(5) ALT(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05NMNMNMNMWang 201235 (18/17)35 (20/15)By intravenous drip infusion of AM injection (50 ml, qd) + basic treatmentAntiviral drugs + vitamin C + coenzyme Q10 + polarization liquid + Trimetazidine4 weeksY(1) Effective rate(2) Arrhythmia(3) cTnI(4) Cardiac function(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.0555±1160±953±1755±16Dong 201160 (34/26)50 (28/22)By intravenous drip infusion of AM injection (5-20 ml, qd) + basic treatmentAntiviral drugs (ribavirin) + vitamin C + fructose + energy mixture injection30 daysN(1) Effective rate(2) Recovery rate of CK-MB(3) Recovery rate of CK(4) Recovery rate of LDH(5) Recovery rate of AST(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.056.56.9NMNMHu 200950 (26/24)50 (27/23)By intravenous drip infusion of AM injection (60 ml, bid) in 5% GS250ml+basic treatmentCoenzyme Q10 + polarization liquid2 weeksY(1) Effective rate(2) Effect of arrhythmia(3) AST(4) CK-MB(5) LDH(6) cTnI(7) NK(8) TNF-α(9) IL-1(10) IL-6(1)P<0.05(2) P<0.05(3) P>0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P>0.05(9) P<0.05(10) P>0.0538±10.135±9.84±0.7 months5±0.6 monthsZhang et al. 2006B33 (20/13)20 (14/6)By intravenous drip infusion of AM injection (5-10 ml, qd) in 5% GS150ml+basic treatmentAntiviral drugs (ribavirin) + vitamin C + vitamin E + energy mixture injection2 weeksN(1) Effective rate(2) CK(3) AST(4) LDH(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.052±112±11NMNMNote:α-HBDH: α-hydroxybutyric dehydrogenase; hs-CRP: hypersensitive C-reactive protein; miR: microRNA; ALT: alanine aminotransferase; AM: Astragalus membranaceus; AST: aspartate aminotransferase; ATP: adenosine triphosphate; Bid: bis in die; cTnI: cardiac troponin I; CD: cluster of differentiation; CK: creatine kinase; CK-MB: creatine kinase isoenzyme; EF: ejection fraction; ESR: erythrocyte sedimentation rate; GS: glucose injection; GST: glutathione transferase; IL: interleukin; INF-γ: interferon-γ; LDH: lactic dehydrogenase; MDA: malondialdehyde; N: no; NK: natural killer cell; NM: not mentioned; NO: nitric oxide; NS: normal saline; Qd: quaque die; SOD: superoxide dismutase; Th: T helper cell; TNF: tumor necrosis factor; Y: yes.Table 2
Information of AM of clinical study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedDu 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Li et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z19993151Qi et al. 2019InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020782Zhang et al. 2019InjectionJiangsu Jiuxu Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z20003189Zheng 2019InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Liu et al. 2018InjectionUnknownUnknownUnknownGui 2017GranuleUnknownUnknownUnknownZhang et al. 2017BInjectionUnknownUnknownUnknownZhou 2017InjectionUnknownUnknownUnknownLi et al. 2016AInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094Xing 2016InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLBatch number: 20120829Wu 2016InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Wu et al. 2016InjectionUnknownUnknownUnknownGao 2015InjectionUnknownUnknownUnknownLou 2015InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z33020178Tao 2015InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13020999Zhao et al. 2015InjectionHarbin Shengtai Biopharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z23020820Ban 2014InjectionUnknownUnknownUnknownWang et al. 2014InjectionDali Pharmaceutical Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z53021585Liang 2014InjectionHeilongjiang Zhenbaodao Pharmaceutical Co., Ltd.2 g/mLBatch number: 100226Kang 2014InjectionUnknownUnknownUnknownZhang 2014GranuleUnknownUnknownUnknownLiu et al. 2013InjectionChengdu Di’ao Jiuhong pharmaceutical factory2 g/mLBatch number: 0210094Zhang et al. 2013InjectionUnknownUnknownUnknownWang 2012InjectionUnknownUnknownUnknownDong 2011InjectionZhengda Qingchunbao Pharmaceutical Co., Ltd.2 g/mLBatch number: 020213210901082, 0506013Hu 2009InjectionShenwei Pharmaceutical Group Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z13021000Zhang et al. 2006BInjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLBatch number: 0210094


## 3.2.2. Animal Studies

The overall characteristics of the included animal study are generalized in Table3. A total of 15 Chinese studies [47–61] and 1 English study [13] on AM for VM published between 2002 and 2017 were included. All studies are involved in 634 experimental animals. Among them, male Balb/c mice were used in 13 studies [13, 47, 49–51, 53, 54, 56–61], female Balb/c mice in 1 study [52], Balb/c mice without mentioning gender in 1 study [55], and male/female SD rats in 1 study [48]. All models of acute VM were established by intraperitoneal injection of a solution containing coxsackievirus B3 (CVB3) virus. Twelve studies [13, 48–51, 53, 56–61] implemented the dose gradient of AM ranged from 2.2 mg•kg−1•d−1 to 90 g•kg−1•d−1. In addition, 1 study [54] used the dosage of AM with 0.4 mg•d−1, 2 studies [52, 55] used 0.4 g•d−1, and 1 study [47] used 0.4 ml•g−1•d−1. Intragastric administration was adopted in 7 studies [13, 53–56, 59, 61] and intraperitoneal injection in 9 studies [47–52, 57, 58, 60]. All included studies reported that the intervention group received AM as monotherapy, while the control group was treated with the same volume of normal saline or nonfunctional liquid therapy or placebo. Detailed information of AM in each animal study is displayed in Table 4. The survival rate of animals was utilized as the primary outcome measure in 4 studies [13, 54, 57, 58], the changes of cardiac pathology or cardiac pathological score in 15 studies [13, 47–55, 57–61], cTnI in 3 studies [13, 47, 50], CK-MB in 3 studies [47, 49, 61], LDH in 2 studies [57, 61], AST in 1 study [57], and none of the included studies involved in the indexes of cardiac function under B-ultrasound. Among secondary outcome indicators for the study of mechanism, tumor necrosis factor (TNF-α) was reported in 4 studies [49, 53, 54, 56]; interleukin-2 (IL-2), interleukin-8 (IL-8), and interleukin-18 (IL-18) in 1 study [52]; nuclear chemokine-1 (MCP-1) in 1 study [51]; macrophage inflammatory protein-2 (MIP-2) in 1 study [50]; superoxide dismutase (SOD) and malondialdehyde (MDA) in 1 study [57]; Caveolin-3 (Cav-3) and Smad family member 3 (Smad3) in 1 study [48]; coxsackievirus and adenoviral receptor (CAR) in surface myocardium in 1 study [55]; sarco endoplasmic reticulum calcium adenosine triphosphatase (SERCA), endothelin-1 (ET-1) and the maximum binding capacity of endothelin receptor maximum binding capacity (ETR Bmax) in 1 study [13]; the replication level of CVB3 in 1 study [59]; the changes of Fas/FasL gene expression in cardiomyocytes in 1 study [60]; and the atrial natriuretic peptide (ANP) in 1 study [13].Table 3
The characteristic of animal studies.
Study (years)Species (age; sex; number = experimental/control)WeightModel (method)Experimental groupControl groupOutcome indexIntergroup differencesZhang et al. 2017ABalb/c mice (4-6 weeks; male; 12/12)16-18 gBy intraperitoneal injection of culture medium containing 1000 PFU/ml CVB3 virus (0.4 ml)By intraperitoneal injection of AM injection (0.4 ml/g, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml/g, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) CK-MB(1)P<0.05(2) P<0.01(3) P<0.01Li et al. 2016BSD rats (7-9 weeks; male/female; 15/15)182±36gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (1.68 g/kg, qd) for 15 d after establishing modelBy intraperitoneal injection of normal saline (20 ml/kg, qd) for 15 d after establishing model(1) Changes of cardiac pathology(2) Caveolin-3(3) Smad-3(1)P<0.05(2) P<0.01(3) P<0.05Jiang 2013Balb/c mice (4-6 weeks; NM; 12/12)NMBy intraperitoneal injection of culture medium containing 2000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 7 d after establishing model(1) Changes of cardiac pathology(2) CK-MB(3) TNF-α(1)P<0.01(2) P<0.01(3) P<0.01Wang et al. 2011Balb/c mice (4 weeks; male; 15/15)12-16 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) MIP-2 mRNA(4) MIP-2(1)P<0.01(2) P<0.05(3) P<0.01(4) P<0.01Cai et al. 2009Balb/c mice (6-8 weeks; male; 20/20)18-22 gBy intraperitoneal injection of culture medium containing 1000 TCID50 CVB3 virus (0.15 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 14 d after establishing modelBy intraperitoneal injection of normal saline (10 g/kg, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) MCP-1 mRNA(3) MCP-1(1)P<0.05(2) P<0.01(3) P<0.05Zhang et al. 2009Balb/c mice (6-8 weeks; female; 20/20)NMBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (0.4 g, qd) for 21 d after establishing modelBy intraperitoneal injection of normal saline (0.2 ml, qd) for 21 d after establishing model(1) Changes of cardiac pathology(2) IL-2(3) IL-8(4) IL-18(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2007Balb/c mice (5 weeks; NM; 40/40)15-16 gBy intraperitoneal injection of culture medium containing 500 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.4 g, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.3 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Coxsackievirus and adenovirus receptor mRNA(1)P<0.01(2) P<0.01Wu et al. 2007Balb/c mice (4 weeks; male; 20/20)14±2gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.2 ml)By oral gavage of AM oral liquid (0.2 mg, bid) for 10 d after establishing modelBy oral gavage of normal saline (0.2 ml, bid) for 10 d after establishing model(1) Changes of cardiac pathology(2) TNF-α mRNA(3) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05Yao et al. 2007Balb/c mice (5 weeks; male; 20/20)16-20 gBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (30 g/kg, qd) for 5 d after establishing modelBy intraperitoneal injection of normal saline (0.1 ml, qd) for 5 d after establishing model(1) Changes of cardiac pathology(2) TNF-α(1)P<0.05(2) P<0.05Chen et al. 2006Balb/c mice (3 weeks; male; 36/31)12-15 gBy intraperitoneal injection of culture medium containing 20000 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (2.2 mg/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) Changes of cardiac pathology(2) cTnI(3) SERCA activity(4) ETR maximum binding capacity(5) ETR equilibrium dissociation constant(6) ET-1(7) ANP(8) Survival rate(1)P<0.05(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05(8) P<0.05Zhang et al. 2006ABalb/c mice (4 weeks; male; 30/30)NMBy intraperitoneal injection of culture medium containing1×108 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM granule (30 g/kg, qd) for 5 d after establishing modelBy oral gavage of normal saline for 5 d after establishing model(1) Cardiomyocyte apoptosis rate(2) TNF-α(1)P<0.05(2) P<0.05Guan et al. 2005Balb/c mice (NM; male; 8/6)17.5±1.2gBy intraperitoneal injection of culture medium containing 400 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (90 g/kg, qd) for 9 d after establishing modelBy intraperitoneal injection of normal saline for 9 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(3) AST(4) LDH(5) MDA(6) SOD(7) Affect of electrocardiogram(1)P<0.01(2) P<0.05(3) P<0.05(4) P<0.05(5) P<0.05(6) P<0.05(7) P<0.05Liu et al. 2004Balb/c mice (45 weeks; male; 50/50)14-16 gBy intraperitoneal injection of culture medium containing 10000 TCID50 CVB3 virus (0.2 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of phosphate buffered solutions (0.2 ml, qd) for 7 d after establishing model(1) Survival rate(2) Changes of cardiac pathology(1)P<0.05(2) P<0.05Liu et al. 2003Balb/c mice (4-6 weeks; male; 12/12)NMBy intraperitoneal injection of culture medium containing1×109 TCID50 CVB3 virus (0.1 ml)By intraperitoneal injection of AM injection (10 g/kg, qd) for 7 d after establishing modelBy intraperitoneal injection of normal saline for 7 d after establishing model(1) Changes of cardiac pathology(2) Apoptotic index(3) Fas(4) FasL(1)P<0.05(2) P<0.01(3) P<0.01(4) P<0.05Li et al. 2003Balb/c mice (6-8 weeks; male; 20/20)16-18 gBy intraperitoneal injection of culture medium containing 100 TCID50 CVB3 virus (0.1 ml)By oral gavage of AM oral liquid (0.78 g/kg, qd) for 14 d after establishing modelBy oral gavage of normal saline (0.5 ml, qd) for 14 d after establishing model(1) Changes of cardiac pathology(2) Virus isolation positive rate(1)P<0.01(2) P>0.05Liu et al. 2002Balb/c mice (NM; male; 10/11)12.8±1.0gBy intraperitoneal injection of culture medium containing9×109 PFU/ml CVB3 virus (0.4 ml)By oral gavage of AM oral liquid (10 g/kg, qd) for 7 d after establishing modelBy oral gavage of normal distilled water for 7 d after establishing model(1) HW/BW ratios(2) Changes of cardiac pathology(3) LDH(4) CK-MB(1)P<0.05(2) P<0.05(3) P<0.01(4) P<0.05Note: d: day; AM: Astragalus membranaceus; ANP: atrial natriuretic peptide; AST: aspartate aminotransferase; Bid: bis in die; cTnI: cardiac troponin I; CK-MB: creatine kinase isoenzyme; CVB3: coxsackievirus B3; ET: endothelin; ETR: endothelin receptor; HW/BW: heart weight/body weight; IL: interleukin; LDH: lactic dehydrogenase; MCP: monocyte chemoattractant protein; MDA: malondialdehyde; MIP: macrophage inflammatory protein; NM: not mentioned; PFU: plaque-forming unit; Qd: quaque die; SERCA: sarco endoplasmic reticulum calcium adenosine triphosphatase; Smad: small mothers against decapentaplegic; SOD: superoxide dismutase; TCID50: median tissue culture infective dose; TNF-α: tumor necrosis factor-α.Table 4
Information of AM of animal study.
Study (years)SpecificationsSourceConcentration (crude drug content)Quality control reportedZhang et al. 2017AInjectionUnknownUnknownUnknownLi et al. 2016BGranuleNanjing Tongrentang Pharmaceutical Co., Ltd.UnknownBatch number: 140604Jiang 2013InjectionFuda Pharmaceutical Co., Ltd.2 g/mLBatch number: 000617Wang et al. 2011InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Cai et al. 2009InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLTraditional Chinese patented medicine WY: Z51021776Zhang et al. 2009InjectionHugang Xinya Pharmaceutical Industry (Yangzhou) Co., Ltd.2 g/mLTraditional Chinese patented medicine WY: Z32021256Li et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownTraditional Chinese patented medicine WY: Z20003380Wu et al. 2007Oral liquidUnion Hospital affiliated Huazhong University of Science and Technology1 g/LBatch number: 020926Yao et al. 2007GranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Chen et al. 2006InjectionFuda Pharmaceutical Co., Ltd.2 g/mLUnknownZhang et al. 2006AGranuleBaili Pharmaceutical Co., Ltd.UnknownBatch number: 030505Guan et al. 2005InjectionShanghai Tiansheng Pharmaceutical Chemical Industry Research Institute12 g/mLBatch number: 20020108Liu et al. 2004InjectionChengdu Di’ao Jiuhong Pharmaceutical Factory2 g/mLUnknownLiu et al. 2003InjectionShanghai Hefeng Pharmaceutical Co., Ltd.2 g/mLUnknownLi et al. 2003Oral liquidUnknown2 g/mLUnknownLiu et al. 2002Oral liquidUnknown1 g/mLUnknown


## 3.3. Study Quality

The number of criteria met in clinical studies varied from 3/7 to 7/7 with the average of 3.32 according to the risk of bias tool recommended by Cochrane Collaboration [17] (The Cochrane Collaboration.http://www.cochrane-handbook.org. (Accessed December 25, 2014)), while the number of criteria met in animal studies varied from 2/10 to 5/10 with an average of 3 according to SYRCLE’s risk of bias tool [18]. Detailed results of methodological quality of clinical and animal studies are presented, respectively, in Tables 5 and 6.Table 5
Risk of bias of clinical studies.
StudyABCDEFGTotalDu 2019+———+—+3Li et al. 2019+———+—+3Qi et al. 2019+———+++4Zhang et al. 2019+———+—+3Zheng 2019+———+—+3Liu et al. 2018+———+++4Gui 2017+———+—+3Zhang et al. 2017B+———+++4Zhou 2017+———+—+3Li et al. 2016A+———+—+3Xing 2016+———+—+3Wu 2016+———+—+3Wu et al. 2016+———+—+3Gao 2015+———+—+3Lou 2015+———+—+3Tao 2015+———+—+3Zhao et al. 2015+———+—+3Ban 2014+———+—+3Wang et al. 2014+———+—+3Liang 2014+———+—+3Kang 2014+———+—+3Zhang 2014+———+—+3Liu et al. 2013+———+++4Zhang et al. 2013+++++++7Wang 2012+———+—+3Dong 2011+———+—+3Hu 2009+———+—+3Zhang et al. 2006B++——+—+4Note: A: random sequence generation; B: concealment of allocation; C: blinding of participants and personnel; D: blinding of outcome assessment; E: incomplete outcome data; F: selective reporting; G: other bias; “+” indicates low risk of bias; “-” indicates high risk of bias; and “?” indicates an unclear risk of bias.Table 6
Risk of bias of animal studies.
StudyABCDEFGHIJTotalZhang et al. 2017A+————+—+++5Li et al. 2016B?——+—+—+?+4Jiang 2013———————+?+2Wang et al. 2011?——+———+?+3Cai et al. 2009?——+———+++4Zhang et al. 2009?——————+?+2Li et al. 2007?——————+++3Wu et al. 2007?————+—+?+3Yao et al. 2007?——————+?+2Chen et al. 2006———————+?+2Zhang et al. 2006A?——————+?+2Guan et al. 2005?——————+?+2Liu et al. 2004+——+———+?+4Liu et al. 2003?+—————+++4Li et al. 2003?+———+—+?+4Liu et al. 2002?——————+?+2Note: A: sequence generation; B: baseline characteristics; C: allocation concealment; D: random housing and animal welfare; E: blinding of caregivers and/or investigators; F: random outcome assessment; G: blinding of outcome assessor; H: complete outcome data; I: selective outcome reporting; J: other sources of bias. “+” indicates low risk of bias; “-” indicates high risk of bias; and “?” indicates an unclear risk of bias.


## 3.4. Effectiveness

### 3.4.1. Outcomes of Clinical Studies

(1) Cardiac Enzymes and Cardiac Troponin. CK-MB was reported in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41], LDH in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45], AST in 7 studies [19, 25, 27, 38, 41, 42, 45], and cTnI in 8 studies [21, 23, 26, 28–30, 35, 37] as primary outcome measures. Among the studies involve in CK-MB, 1 study [37] was designed to contrast the efficacy of AI and placebo for VM; 13 studies [19, 21, 22, 25–31, 35, 38, 41] were designed to contrast the efficacy of AI plus basic treatment and basic treatment. Meta-analysis of the 13 studies revealed significant effects of AI plus basic treatment on decreasing CK-MB in patients with VM (n=1266, SMD −1.58, 95% CI [−1.72 to −1.45], P<0.00001; heterogeneity: χ2=221.59, df=12 (P<0.00001); I2=95%, Figure 2). The remaining one study [37] showed that CK-MB was decreased evidently by AI contrast with the placebo group. Meta-analysis of 10 studies and 7 studies showed separately that AI plus basic treatment could decrease LDH (n=913, SMD −0.89, 95% CI [−1.03 to −0.76], P<0.00001; heterogeneity: χ2=19.43, df=9 (P=0.02); I2=54%, Figure 3) and AST (n=611, SMD −0.82, 95% CI [−0.99 to −0.65], P<0.00001; heterogeneity: χ2=53.14, df=6 (P<0.00001); I2=89%, Figure 4) significantly in patients with VM. As for cTnI, meta-analysis of 8 studies showed significant effects of AI plus basic treatment on reducing cTnI in patients with VM (n=770, SMD −1.71, 95% CI [−1.88 to −1.53], P<0.00001; heterogeneity: χ2=121.49, df=7 (P<0.00001); I2=94%, Figure 5). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in CK-MB, AST, or cTnI.Figure 2
The forest plot: effects of AM for decreasing CK-MB compared with the control group (clinical studies).Figure 3
The forest plot: effects of AM for decreasing LDH compared with the control group (clinical studies).Figure 4
The forest plot: effects of AM for decreasing AST compared with the control group (clinical studies).Figure 5
The forest plot: effects of AM for decreasing cTnI compared with the control group (clinical studies).(2) Effective Rate of Clinical Treatment. The effective rate of clinical treatment was reported in 25 studies [19–23, 25–28, 30–36, 38–46] to contrast the efficacy of AI or AM granule plus basic treatment and basic treatment, except 1 comparative study [37] of AI and placebo. Meta-analysis of the 25 studies showed significant effects of AI plus basic treatment on increasing the effective rate of clinical treatment compared with basic treatment (n=2245, RR 1.24, 95% CI [1.19 to 1.28], P<0.00001; heterogeneity: χ2=16.71, df=24 (P=0.86); I2=0%, Figure 6). The symmetrical publication bias funnel indicated that there is no obvious publication bias in this study (Figure 7). The remaining 1 study also showed that the efficacy of AI in the treatment of VM was significantly better than that in the placebo group (P<0.05).Figure 6
The forest plot: effects of AM for increasing the effective rate of clinical treatment compared with the control group.Figure 7
The funnel plot: effects of AM on an effective rate of clinical treatment.(3) Adverse Reactions. Adverse reactions were reported in 10 studies [19, 26–29, 32, 33, 36, 37, 39]. Serious adverse reactions such as liver and kidney function injury, anaphylactic shock, carcinogenesis, and teratogenesis were not mentioned in the included studies. No statistical difference was found in gastrointestinal discomfort reported as the most common adverse reaction (P>0.05).


### 3.4.2. Outcomes of Animal Studies

(1) Survive Rate. A meta-analysis of 4 studies [13, 54, 57, 58] showed that AM induces a significant improvement in the survive rate of VM animals, compared with the control group (n=227, RR 1.58, 95% CI [1.29 to 1.92], P<0.0001; heterogeneity: χ2=1.08, df=3 (P=0.78); I2=0%, Figure 8).Figure 8
The forest plot: effects of AM for increasing the survive rate of VM animals.(2) Cardiac Pathology. Cardiac pathology was reported in 15 studies [13, 47–55, 57–61]. Among them, 12 studies [13, 47–51, 53–55, 59–61] calculated cardiac pathological score with reference to the method proposed by Siasos et al. [62]. Meta-analysis of these studies showed significant effects of AM on reducing cardiac pathological score in animals with VM (n=246, MD −1.18, 95% CI [−1.31 to −1.05], P<0.0001; heterogeneity: χ2=17.70, df=11 (P=0.09); I2=38%, Figure 9). Among other studies, AM treatment significantly promoted the growth of cardiac fibroblasts in 1 study [52]. Astragalus inhibited the hypertrophy of cardiomyocyte in 1 study [58]. Astragalus inhibited the infiltration of inflammatory cell in 1 study [57].Figure 9
The forest plot: effects of AM for decreasing cardiac pathological score compared with the control group (animal studies).(3) Cardiac Enzymes and Cardiac Troponin. Meta-analysis of 3 studies [47, 49, 61] indicated significant effects of AM on reducing CK-MB in VM animals compared with control group (n=63, SMD −1.65, 95% CI [−2.33 to −0.98], P<0.00001; heterogeneity: χ2=25.62, df=2 (P<0.00001); I2=92%). After sensitivity analyses, we removed 1 study [47] that used AM at a dose of 0.4 ml/g. Meta-analysis of 2 studies [49, 61] showed significant effects of AM on reducing CK-MB (n=39, SMD −1.20, 95% CI [−1.90 to −0.50], P<0.00001; heterogeneity: χ2=0.75, df=1 (P=0.39); I2=0%, Figure 10). Meta-analysis of 2 studies [57, 61] showed significant effects of AM on decreasing LDH compared with the control group (n=42, SMD −1.04, 95% CI [−1.71 to −0.38], P<0.00001; heterogeneity: χ2=0.01, df=1 (P=0.91); I2=0%, Figure 11). Meta-analysis of 3 studies [13, 47, 50] showed significant effects of AM on decreasing cTnI compared with the control group (n=68, SMD −2.39, 95% CI [−3.13 to −1.65], P<0.00001; heterogeneity: χ2=25.23, df=2 (P<0.00001); I2=92%, Figure 12). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in cTnI.Figure 10
The forest plot: effects of AM for decreasing CK-MB compared with the control group (animal studies).Figure 11
The forest plot: effects of AM for decreasing LDH compared with the control group (animal studies).Figure 12
The forest plot: effects of AM for decreasing cTnI compared with the control group (animal studies).(4) Cardioprotective Mechanisms. Meta-analysis of 3 studies [49, 53, 56] showed significant effects of AM on decreasing TNF-α compared with the control group in VM animal (n=84, SMD −2.02, 95% CI [−2.57 to −1.48], P<0.00001; heterogeneity: χ2=0.54, df=2 (P=0.77); I2=0%, Figure 13); 1 study [52] for reducing IL-2, IL-8, and IL-18 (P<0.05); 1 study [51] for reducing MCP-1 (P<0.05); 1 study [50] for reducing MIP-2 (P<0.05); 1 study [57] for reducing MDA (P<0.05) and increasing SOD (P<0.05); 1 study [55] for reducing the expression of CAR (P<0.05); 1 study [48] for reducing Cav-3 and Smad3 (P<0.05); 1 study [13] for reducing ET-1, ANP, and ETR Bmax (P<0.05) and increasing the activity of SERCA (P<0.05), and 1 study [60] for reducing the expression of Fas and FasL (P<0.05).Figure 13
The forest plot: effects of AM for decreasing TNF-α compared with the control group (animal studies).


## 3.4.1. Outcomes of Clinical Studies

(1) Cardiac Enzymes and Cardiac Troponin. CK-MB was reported in 14 studies [19, 21, 22, 25–31, 35, 37, 38, 41], LDH in 10 studies [20, 22, 23, 25, 27, 30, 35, 38, 41, 45], AST in 7 studies [19, 25, 27, 38, 41, 42, 45], and cTnI in 8 studies [21, 23, 26, 28–30, 35, 37] as primary outcome measures. Among the studies involve in CK-MB, 1 study [37] was designed to contrast the efficacy of AI and placebo for VM; 13 studies [19, 21, 22, 25–31, 35, 38, 41] were designed to contrast the efficacy of AI plus basic treatment and basic treatment. Meta-analysis of the 13 studies revealed significant effects of AI plus basic treatment on decreasing CK-MB in patients with VM (n=1266, SMD −1.58, 95% CI [−1.72 to −1.45], P<0.00001; heterogeneity: χ2=221.59, df=12 (P<0.00001); I2=95%, Figure 2). The remaining one study [37] showed that CK-MB was decreased evidently by AI contrast with the placebo group. Meta-analysis of 10 studies and 7 studies showed separately that AI plus basic treatment could decrease LDH (n=913, SMD −0.89, 95% CI [−1.03 to −0.76], P<0.00001; heterogeneity: χ2=19.43, df=9 (P=0.02); I2=54%, Figure 3) and AST (n=611, SMD −0.82, 95% CI [−0.99 to −0.65], P<0.00001; heterogeneity: χ2=53.14, df=6 (P<0.00001); I2=89%, Figure 4) significantly in patients with VM. As for cTnI, meta-analysis of 8 studies showed significant effects of AI plus basic treatment on reducing cTnI in patients with VM (n=770, SMD −1.71, 95% CI [−1.88 to −1.53], P<0.00001; heterogeneity: χ2=121.49, df=7 (P<0.00001); I2=94%, Figure 5). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in CK-MB, AST, or cTnI.Figure 2
The forest plot: effects of AM for decreasing CK-MB compared with the control group (clinical studies).Figure 3
The forest plot: effects of AM for decreasing LDH compared with the control group (clinical studies).Figure 4
The forest plot: effects of AM for decreasing AST compared with the control group (clinical studies).Figure 5
The forest plot: effects of AM for decreasing cTnI compared with the control group (clinical studies).(2) Effective Rate of Clinical Treatment. The effective rate of clinical treatment was reported in 25 studies [19–23, 25–28, 30–36, 38–46] to contrast the efficacy of AI or AM granule plus basic treatment and basic treatment, except 1 comparative study [37] of AI and placebo. Meta-analysis of the 25 studies showed significant effects of AI plus basic treatment on increasing the effective rate of clinical treatment compared with basic treatment (n=2245, RR 1.24, 95% CI [1.19 to 1.28], P<0.00001; heterogeneity: χ2=16.71, df=24 (P=0.86); I2=0%, Figure 6). The symmetrical publication bias funnel indicated that there is no obvious publication bias in this study (Figure 7). The remaining 1 study also showed that the efficacy of AI in the treatment of VM was significantly better than that in the placebo group (P<0.05).Figure 6
The forest plot: effects of AM for increasing the effective rate of clinical treatment compared with the control group.Figure 7
The funnel plot: effects of AM on an effective rate of clinical treatment.(3) Adverse Reactions. Adverse reactions were reported in 10 studies [19, 26–29, 32, 33, 36, 37, 39]. Serious adverse reactions such as liver and kidney function injury, anaphylactic shock, carcinogenesis, and teratogenesis were not mentioned in the included studies. No statistical difference was found in gastrointestinal discomfort reported as the most common adverse reaction (P>0.05).


## 3.4.2. Outcomes of Animal Studies

(1) Survive Rate. A meta-analysis of 4 studies [13, 54, 57, 58] showed that AM induces a significant improvement in the survive rate of VM animals, compared with the control group (n=227, RR 1.58, 95% CI [1.29 to 1.92], P<0.0001; heterogeneity: χ2=1.08, df=3 (P=0.78); I2=0%, Figure 8).Figure 8
The forest plot: effects of AM for increasing the survive rate of VM animals.(2) Cardiac Pathology. Cardiac pathology was reported in 15 studies [13, 47–55, 57–61]. Among them, 12 studies [13, 47–51, 53–55, 59–61] calculated cardiac pathological score with reference to the method proposed by Siasos et al. [62]. Meta-analysis of these studies showed significant effects of AM on reducing cardiac pathological score in animals with VM (n=246, MD −1.18, 95% CI [−1.31 to −1.05], P<0.0001; heterogeneity: χ2=17.70, df=11 (P=0.09); I2=38%, Figure 9). Among other studies, AM treatment significantly promoted the growth of cardiac fibroblasts in 1 study [52]. Astragalus inhibited the hypertrophy of cardiomyocyte in 1 study [58]. Astragalus inhibited the infiltration of inflammatory cell in 1 study [57].Figure 9
The forest plot: effects of AM for decreasing cardiac pathological score compared with the control group (animal studies).(3) Cardiac Enzymes and Cardiac Troponin. Meta-analysis of 3 studies [47, 49, 61] indicated significant effects of AM on reducing CK-MB in VM animals compared with control group (n=63, SMD −1.65, 95% CI [−2.33 to −0.98], P<0.00001; heterogeneity: χ2=25.62, df=2 (P<0.00001); I2=92%). After sensitivity analyses, we removed 1 study [47] that used AM at a dose of 0.4 ml/g. Meta-analysis of 2 studies [49, 61] showed significant effects of AM on reducing CK-MB (n=39, SMD −1.20, 95% CI [−1.90 to −0.50], P<0.00001; heterogeneity: χ2=0.75, df=1 (P=0.39); I2=0%, Figure 10). Meta-analysis of 2 studies [57, 61] showed significant effects of AM on decreasing LDH compared with the control group (n=42, SMD −1.04, 95% CI [−1.71 to −0.38], P<0.00001; heterogeneity: χ2=0.01, df=1 (P=0.91); I2=0%, Figure 11). Meta-analysis of 3 studies [13, 47, 50] showed significant effects of AM on decreasing cTnI compared with the control group (n=68, SMD −2.39, 95% CI [−3.13 to −1.65], P<0.00001; heterogeneity: χ2=25.23, df=2 (P<0.00001); I2=92%, Figure 12). The heterogeneity did not decrease significantly after sensitive analysis or removing any study involve in cTnI.Figure 10
The forest plot: effects of AM for decreasing CK-MB compared with the control group (animal studies).Figure 11
The forest plot: effects of AM for decreasing LDH compared with the control group (animal studies).Figure 12
The forest plot: effects of AM for decreasing cTnI compared with the control group (animal studies).(4) Cardioprotective Mechanisms. Meta-analysis of 3 studies [49, 53, 56] showed significant effects of AM on decreasing TNF-α compared with the control group in VM animal (n=84, SMD −2.02, 95% CI [−2.57 to −1.48], P<0.00001; heterogeneity: χ2=0.54, df=2 (P=0.77); I2=0%, Figure 13); 1 study [52] for reducing IL-2, IL-8, and IL-18 (P<0.05); 1 study [51] for reducing MCP-1 (P<0.05); 1 study [50] for reducing MIP-2 (P<0.05); 1 study [57] for reducing MDA (P<0.05) and increasing SOD (P<0.05); 1 study [55] for reducing the expression of CAR (P<0.05); 1 study [48] for reducing Cav-3 and Smad3 (P<0.05); 1 study [13] for reducing ET-1, ANP, and ETR Bmax (P<0.05) and increasing the activity of SERCA (P<0.05), and 1 study [60] for reducing the expression of Fas and FasL (P<0.05).Figure 13
The forest plot: effects of AM for decreasing TNF-α compared with the control group (animal studies).


## 3.5. Subgroup Analysis

The potential confounding factors (including age of animals, varying methods of administration, varying doses of AM, and various durations of treatment) that may increase the heterogeneity of outcome measures were explored using stratified analysis of cardiac pathological score. In the subgroup analysis of age of Balb/c mice, the effect size of the model used mature mice (≥6 weeks) showed better results than immature mice (<6 weeks) (SMD −1.40 vs. SMD −0.97,P=0.009, Figure 14(d)), and the heterogeneity of two groups decreased obviously. No difference was seen between the intraperitoneal injection group and oral gavage group (SMD −1.01 vs. SMD −1.28, P=0.06, Figure 14(c)). The heterogeneity of the two groups decreased insignificantly. In the subgroup analysis of durations of treatment, the longer period of AM treatment (>10 days) showed better effect size than the shorter treatment (≤10 days) (SMD −1.28 vs. SMD −1.01, P=0.05, Figure 14(a)), and the heterogeneity of the longer period group decreased significantly. No difference was seen between the high dose of AM group (≥10 g/kg) and low-dose group (<10 g/kg) (SMD −1.08 vs. SMD −1.15, P=0.15, Figure 14(b)), and the heterogeneity of two groups decreased insignificantly.Figure 14
Effect of AM on cardiac pathological score in subgroups. (a) Duration of treatment; (b) AM dose; (c) induction type; (d) age of animals.#P>0.05 vs. control groups; ∗P≤0.05 vs. control groups.
(a)(b)(c)(d)


## 4. Discussion

### 4.1. Summary of Evidence

This is a first-ever systematic review, which includes 28 randomized clinical control studies with 2522 participants and 16 animal studies with 634 animals to comprehensively and systematically evaluate the efficacy, safety, and possible mechanisms of AM in the treatment of VM. The quality of the studies included was generally moderate. The evidence available from the present study showed a cardioprotective function of AM for VM animals and patients by multiple mechanisms.


### 4.2. Limitations

There are some limitations of the present study: (1) English and Chinese literatures were included only in the present study, which may lead to a certain degree of selection bias; (2) All patients were patients with mild viral myocarditis, which may exaggerate the therapeutic effect of AM; (3) clinical adverse reactions were seldom to be reported; (4) most of the included clinical studies are short-term follow-up studies with small sample size; (5) the studies selected for our analysis had methodological deficiencies, such as seldom using allocation concealment and the blind method.


### 4.3. Implications

The results of subgroup analysis showed that AM reduced the cardiac pathological score of mature Balb/c mice with VM significantly better than that of immature Balb/c mice (SMD −1.40 vs. SMD −0.97,P=0.009), which suggests that the age of mice may be the source of high heterogeneity. It may be related to CAR which is the receptor that binds to the Coxsackie virus on cardiomyocytes [63]. The study from Li and Yi showed that the expression of CAR in the myocardium of mice infected with CVB3 increased significantly and reached a peak on the 7th day after infection, and the disease was aggravated simultaneously [55]. However, the expression of CAR decreased significantly after AM treatment [55]. Thus, we draw a conclusion that CAR plays a key role in the process of infection of CVB3 into target cells, and AM was able to downregulate it. Ito et al. [64] found that CAR was abundant in the hearts of newborn rats but was barely detectable in the hearts of adult rats, which is regarded as one of the crucial reasons that CVB3 tends to infect children and causes severe impact. In addition, eliminating CAR was found to prevent signs of inflammatory cardiomyopathy, with essentially no pathology in animal hearts [65]. And the deletion of CAR at the later stage of mice embryo (≥11days) has no effect on the survival of many embryos to adulthood and heart development [66]. Thus, the development of drugs that inhibit the expression of CAR may be an important direction in the future treatment of VM, especially in children.The results of another subgroup analysis showed that the longer period of AM treatment (>10 days) showed better effect size than the shorter treatment (≤10 days) (SMD −1.28 vs. SMD −1.01,P=0.05), which suggests that the duration of treatment may be the source of high heterogeneity. Myocardial injury caused by VM can be subdivided into two stages. In the early few days of the VM, virus replication causes the exposure of intracellular antigens, myocyte necrosis, and activation of the host’s immune system. The specific performance is the invasion of NK cells and macrophages followed by T lymphocytes. The subacute stage covers few weeks to several months [7]. It is characterized by activated virus-specific T lymphocytes, which may target the host’s organs by molecular mimicry. Two studies [55, 59] reported that AM inhibited the replication of CVB3 and directly reduced the cardiac damage caused by viral replication at the acute stage. In addition, AM also inhibited the activation of T lymphocytes by inhibiting the expression of cytokines (TNF-α [49, 53, 56], IL-8 [52], MCP-1 [51], and MIP-2 [50]) and reducing myocardial injury at the immune reactions stage (subacute stage). The evidences above suggest that long-term (≥10 days) AM treatment may bring greater benefits to VM. However, there are few studies on multiple time points to measure the main outcome indicators at the current stage. Thus, we suggest that further clinical studies or animal experiments could verify the above theory.The therapeutic effect of myocarditis was significantly related to the severity of the disease. However, in all the animal studies included, no classification of the mice according to the severity of myocarditis was done. Meanwhile, in all the clinical trials, patients were all with mild viral myocarditis, and no deaths were reported. Thus, with the available primary data, it is impossible to do subgroup analysis according to disease severity. We recommend that the severity of myocarditis should be considered and classified in future studies.It is reported that low-quality trials have a statistically significant 30–50% exaggeration of treatment efficacy compared with high-quality trials [67]. The quality of the included studies in the present study was considered to be moderate to inferior, with 3-7 points for clinical studies, and 2-5 points for animal studies. Most of the studies had methodological deficiencies, such as seldom using allocation concealment and the blind method. In addition, except for the major projects supported by the fund, few studies have registered experiments in advance or published protocols, which may lead to selective reporting bias [68]. Poor experimental design is a major obstacle to translating preclinical animal research into clinical treatments for human diseases [68]. Thus, we recommend that clinical research should refer to the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement [69], animals research should refer to the ARRIVE (The Animal Research: Reporting In Vivo Experiments) guidelines [70], and the use of allocation concealment and blinding should pay more attention to both clinical and animal research. Moreover, multiple details related to animal treatment, such as anesthesia, analgesia, nutrition, environment (temperature, humidity), and euthanasia, should be recorded in detail, as the lack of humane treatment for animals may also affect the accuracy of the results [70]. Animal research should be registered prior to its execution in a generally accessible database (http://www.crd.york.ac.uk/PROSPERO), and clinical research should be registered (http://www.clinicaltrials.com). It allows verification of the predefined study hypothesis and end-points of the study and reduces publication bias [71].The possible mechanisms of AM mediated cardioprotection in the included studies are summed up as follows: (1) anti-inflammation by reducing TNF-α [49, 53, 56], IL-8 [52], MCP-1 [51], and MIP-2 [50] and increasing IL-18 and IL-2 [52]; (2) antioxidant effects by increasing SOD to reduce the release of MDA [57]; (3) alleviating myocardial fibrosis by inhibiting Cav-3 and TGF-β1 to reduce the expression of Smad3 [48]; (4) inhibiting apoptosis by downregulating gene transcription of Fas/Fasl and reducing the expression of caspase-3 [59]; (5) reducing the calcium overload in sarcoplasmic reticulum to maintain diastolic and systolic of cardiomyocytes by enhancing the activity of SERCA [13]; (6) improving cardiac remodeling by upregulating ETR affinity and reducing the expression of ET-1 and ANP [13]; and (7) inhibiting virus infection and replication by reducing the expression of CAR [55]. The mechanism is summarized in Figure 15.Figure 15
A schematic representation of mechanisms of AM for VM.


## 4.1. Summary of Evidence

This is a first-ever systematic review, which includes 28 randomized clinical control studies with 2522 participants and 16 animal studies with 634 animals to comprehensively and systematically evaluate the efficacy, safety, and possible mechanisms of AM in the treatment of VM. The quality of the studies included was generally moderate. The evidence available from the present study showed a cardioprotective function of AM for VM animals and patients by multiple mechanisms.


## 4.2. Limitations

There are some limitations of the present study: (1) English and Chinese literatures were included only in the present study, which may lead to a certain degree of selection bias; (2) All patients were patients with mild viral myocarditis, which may exaggerate the therapeutic effect of AM; (3) clinical adverse reactions were seldom to be reported; (4) most of the included clinical studies are short-term follow-up studies with small sample size; (5) the studies selected for our analysis had methodological deficiencies, such as seldom using allocation concealment and the blind method.


## 4.3. Implications

The results of subgroup analysis showed that AM reduced the cardiac pathological score of mature Balb/c mice with VM significantly better than that of immature Balb/c mice (SMD −1.40 vs. SMD −0.97,P=0.009), which suggests that the age of mice may be the source of high heterogeneity. It may be related to CAR which is the receptor that binds to the Coxsackie virus on cardiomyocytes [63]. The study from Li and Yi showed that the expression of CAR in the myocardium of mice infected with CVB3 increased significantly and reached a peak on the 7th day after infection, and the disease was aggravated simultaneously [55]. However, the expression of CAR decreased significantly after AM treatment [55]. Thus, we draw a conclusion that CAR plays a key role in the process of infection of CVB3 into target cells, and AM was able to downregulate it. Ito et al. [64] found that CAR was abundant in the hearts of newborn rats but was barely detectable in the hearts of adult rats, which is regarded as one of the crucial reasons that CVB3 tends to infect children and causes severe impact. In addition, eliminating CAR was found to prevent signs of inflammatory cardiomyopathy, with essentially no pathology in animal hearts [65]. And the deletion of CAR at the later stage of mice embryo (≥11days) has no effect on the survival of many embryos to adulthood and heart development [66]. Thus, the development of drugs that inhibit the expression of CAR may be an important direction in the future treatment of VM, especially in children.The results of another subgroup analysis showed that the longer period of AM treatment (>10 days) showed better effect size than the shorter treatment (≤10 days) (SMD −1.28 vs. SMD −1.01,P=0.05), which suggests that the duration of treatment may be the source of high heterogeneity. Myocardial injury caused by VM can be subdivided into two stages. In the early few days of the VM, virus replication causes the exposure of intracellular antigens, myocyte necrosis, and activation of the host’s immune system. The specific performance is the invasion of NK cells and macrophages followed by T lymphocytes. The subacute stage covers few weeks to several months [7]. It is characterized by activated virus-specific T lymphocytes, which may target the host’s organs by molecular mimicry. Two studies [55, 59] reported that AM inhibited the replication of CVB3 and directly reduced the cardiac damage caused by viral replication at the acute stage. In addition, AM also inhibited the activation of T lymphocytes by inhibiting the expression of cytokines (TNF-α [49, 53, 56], IL-8 [52], MCP-1 [51], and MIP-2 [50]) and reducing myocardial injury at the immune reactions stage (subacute stage). The evidences above suggest that long-term (≥10 days) AM treatment may bring greater benefits to VM. However, there are few studies on multiple time points to measure the main outcome indicators at the current stage. Thus, we suggest that further clinical studies or animal experiments could verify the above theory.The therapeutic effect of myocarditis was significantly related to the severity of the disease. However, in all the animal studies included, no classification of the mice according to the severity of myocarditis was done. Meanwhile, in all the clinical trials, patients were all with mild viral myocarditis, and no deaths were reported. Thus, with the available primary data, it is impossible to do subgroup analysis according to disease severity. We recommend that the severity of myocarditis should be considered and classified in future studies.It is reported that low-quality trials have a statistically significant 30–50% exaggeration of treatment efficacy compared with high-quality trials [67]. The quality of the included studies in the present study was considered to be moderate to inferior, with 3-7 points for clinical studies, and 2-5 points for animal studies. Most of the studies had methodological deficiencies, such as seldom using allocation concealment and the blind method. In addition, except for the major projects supported by the fund, few studies have registered experiments in advance or published protocols, which may lead to selective reporting bias [68]. Poor experimental design is a major obstacle to translating preclinical animal research into clinical treatments for human diseases [68]. Thus, we recommend that clinical research should refer to the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement [69], animals research should refer to the ARRIVE (The Animal Research: Reporting In Vivo Experiments) guidelines [70], and the use of allocation concealment and blinding should pay more attention to both clinical and animal research. Moreover, multiple details related to animal treatment, such as anesthesia, analgesia, nutrition, environment (temperature, humidity), and euthanasia, should be recorded in detail, as the lack of humane treatment for animals may also affect the accuracy of the results [70]. Animal research should be registered prior to its execution in a generally accessible database (http://www.crd.york.ac.uk/PROSPERO), and clinical research should be registered (http://www.clinicaltrials.com). It allows verification of the predefined study hypothesis and end-points of the study and reduces publication bias [71].The possible mechanisms of AM mediated cardioprotection in the included studies are summed up as follows: (1) anti-inflammation by reducing TNF-α [49, 53, 56], IL-8 [52], MCP-1 [51], and MIP-2 [50] and increasing IL-18 and IL-2 [52]; (2) antioxidant effects by increasing SOD to reduce the release of MDA [57]; (3) alleviating myocardial fibrosis by inhibiting Cav-3 and TGF-β1 to reduce the expression of Smad3 [48]; (4) inhibiting apoptosis by downregulating gene transcription of Fas/Fasl and reducing the expression of caspase-3 [59]; (5) reducing the calcium overload in sarcoplasmic reticulum to maintain diastolic and systolic of cardiomyocytes by enhancing the activity of SERCA [13]; (6) improving cardiac remodeling by upregulating ETR affinity and reducing the expression of ET-1 and ANP [13]; and (7) inhibiting virus infection and replication by reducing the expression of CAR [55]. The mechanism is summarized in Figure 15.Figure 15
A schematic representation of mechanisms of AM for VM.


## 5. Conclusion

Our findings indicate that AM exerted cardioprotective function in VM animals and patients largely through antivirus and antivirus receptors, anti-inflammatory, antioxidation, antiapoptotic, antifibrosis, and reducing cardiac calcium load. However, due to methodological deficiencies in the original study, current research results need to be treated with caution, and further evidence from future high-quality clinical and animal studies is needed. In conclusion, AM is a potential cardioprotective candidate in the treatment of VM.



---

*Source: 1560353-2020-11-02.xml*